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1. Introduction 
1.1. Allogeneic hematopoietic stem cell transplantation 
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for 
various hematological malignant and non-malignant otherwise fatal diseases. In 1957. Nobel 
prize winner E.D. Thomas performed first human twin transplant for leukemia. 1 In 1959 
Mathé performed first bone marrow transplants for radiation accident victims. 2 In the 1960s, 
additional information regarding the HLA system became available; the serologic HLA 
typing method was developed resulting with first successful HLA-matched sibling transplant 
for SCID in 1968. 3,4,5 First successful complete engraftment and survival of over 1 year was 
reported by Mathé et.al as well as description of acute and chronic GVHD in men. 6,7 In 
1970’s clinical bone marrow transplantation takes off, in early 70’s Thomas performed first 
successful bone marrow transplantation for severe aplastic anemia and in 1977. one hundred 
patients with acute leukemia were treated by chemotherapy, total body irradiation, and 
allogeneic bone marrow transplantation from HLA matched sibling donor. Ninety-four 
patients were engrafted and only one patient rejected the graft. Thirteen patients are alive with 
a marrow graft, on no maintenance antileukemic therapy, and without recurrent leukemia 1-
4.5 years after transplantation. 8 The principle of treating malignant hematological diseases by 
allogeneic stem cell transplant is to permit allogenic, immunologically competent cells to act 
against the host's leukemic cells. 6 Such an effect may be achieved by administration of high 
dose chemotherapy as part of the conditioning regimen followed by allogeneic stem cell 
transplant infusion. The donor immune system recognizes residual tumor cells as foreign and 
eradicates them via the graft-versus-leukemia (GVL) effect. Barnes and Loutit first described 
the graft versus tumor effect of transplanted spleen cells in experimental murine models and 
Mathé in humans. 9,7 The first direct demonstration of clinical GVT effect was the successful 
application of DLIs to treat relapsed CML. 10 The graft versus host disease was first described 
as "secondary syndrome" in humans and runting syndrome in mice. Since 1980’s – 2000’s the 
improvement were made in supportive care, GVHD prophylaxis, better management of early 
complications, new stem cell sources, new indications, DNA-based tissue typing, new 
conditioning regimens with less toxicity were introduced, resulting in improved outcomes, 
older patients appropriate for transplant, the rise cord blood transplantation, etc. Nevertheless, 
acute and chronic GVHD remain a major contributor to transplant-related deaths and very 
significant barrier to successful allo-HSCT. 11, 12 
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The number of allogeneic transplantations continues to increase with more than 25 000 
performed annually. 12 Now days patients are followed for 10 or more years after allo-HSCT. 
Recent study by Gooley et al. had shown substantial reduction in the hazard of death related 
to allogeneic transplantation and improved long-term survival after allo-HSCT due to 
reduction in organ damage, infection and severe acute graft versus host disease (GVHD). 13 
However long-term survivors experience the burden of long-term complications such as 
chronic GVHD, metabolic, endocrinology abnormalities, decreased quality of life and 
secondary malignances. Mortality rates remain twice as high as that of the general population 
among 15-year survivors of HCT and relapse and chronic GVHD were the leading cause of 
premature death in survivors more than 2 years after allo-HSCT. 14  
1.2. Graft-versus-host-disease 
Fifty years ago Billingham formulated three requirements for the development of GVHD: the 
graft must contain immunologically competent cells; the recipient must express tissue 
antigens that are not present in the transplant donor; and the recipient must be incapable of 
mounting an effective response to eliminate the transplanted cells. 15 
Important changes in clinical considerations 
The time of onset became an arbitrary criterion, and it has become more meaningful to define 
the disease on the basis of clinical and histological findings. Accordingly, the commonly use 
day -100 posttransplantation cutoff to separate acute from chronic GVHD is no longer 
satisfactory and the 2005 NIH consensus defined that clinical manifestations rather than time 
from transplant should determine the presence of acute or chronic GVHD. (Figure 1.) NIH 
classification includes persistent, recurrent or late acute GVHD (after day-100) and an overlap 
syndrome (with both acute and chronic GVHD features). 16  
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Figure 1. GVHD classification after NIH consensus                Courtesy of Prof SZ Pavletic 
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1.2.1. Acute graft versus host disease  
Acute GVHD remains a common complication after allo-HSCT and represent one of the most 
significant barriers to successful allo-HSCT and significant cause of treatment failure after 
transplantation, accounting for a substantial portion of early transplant morbidity and 
mortality. The most important factors that are responsible for alloreactivity include donor-
host tolerance mechanisms and the use of immunosuppression. The three key major events in 
pathophysiology of acute GVHD include: 1) tissue damage from the conditioning regimen – 
leading to activation of antigen presenting cells and secretion of proinflammatory cytokines 
such as IL-1 and TNF-α 2) donor T-cell activation against recipient antigen in the context of 
MHC, and 3) an inflammatory response manifested by T-cell cytotoxic response against the 
host tissues (skin, gut, or liver). 17 (Figure 2.) 
Polymorphisms for cytokines that are involved in "cytokine storm" are also risk factors for 
developing GVHD. 18 
The incidence of aGVHD is directly related to the degree of HLA mismatch. 19 
Class I HLA (A, B, and C) antigens are expressed on almost every nucleated cell in the 
organism and class II HLA (DR, DQ, and DP) are primarily expressed on hematopoietic cells 
(monocytes, dendritic cells, B-cells).  In addition to class I and class II HLA antigens also 
"minor" histocompatibility antigens, such as HY and HA-3 represent a target for both GVHD 
and GVL. 20 
Clinically relevant, grade II-IV acute GVHD occurs in 35-45 % of patients who receive grafts 
from matched related donors, and in 60-80% in recipient’s one antigen mismatched unrelated 
donor grafts. 21, 22 
The broad category of aGVHD includes classic acute GVHD (maculopapular erythematous 
rash, gastrointestinal symptoms and cholestatic hepatitis), occurring within 100 days after 
transplant or donor lymphocyte infusion, while persistent recurrent or late aGVHD (usually 
seen after withdrawal of immunosuppression) occurs beyond 100 days of transplantation or 
DLI. Both aGVHD subentities should occur without the presence of diagnostic or distinctive 
cGVHD manifestations. The newly defined entity, "late onset" of aGVHD has been shown to 
be highly associated with poor survival when cGVHD where reclassified according to new 
definition.23,24 
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Figure 2. Pathophysiology of aGVHD                                                                 Internet source 
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The conditions that increase risk for acute GVHD are listed in Table 1. 25 
 
Table 1. Risk factors for acute graft versus host disease 
 
 
Donor recipient factors            Stem cell graft factors     Transplant related 
HLA mismatch  PBSC > BM > UCB   Myeloablative > RIC  
ABO incompatibility     
Unrelated donor     
Older donor     
Multiparity      
CMV seropositivity     
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Combination of cyclosporine and pulse doses of methotrexate is the most often use 
pharmacologic prophylaxis of acute GVHD. Cyclosporine inhibits IL-2 mediated T-cell 
inhibition via inhibition of calcineurin. Methotrexate impairs purine synthesis in T-cells and 
prevents T-cell expansion. Other immunosuppressants such as tacrolimus, sirolimus (mTOR 
inhibitor) or mycophenolate-mofetil are also used. Clinical manifestations of acute GVHD 
include skin changes, diarrhea and liver impairment. Skin is the most commonly and usually 
the first affected organ and nearly half of the patients have skin involvement as only GVHD 
manifestation. The most common sign of aGVHD of the skin is maculopapular exanthema. 
Typically, a rash is appearing on palms and soles and it is highly suggestive for aGVHD and 
the presence of rash at these localizations helps differentiate between aGVHD and 
medicamentosus rash that generally spares these areas. The gastrointestinal tract is second 
most commonly affected organ. Symptoms of the upper GI involvement include anorexia, 
nausea, and dyspepsia, and the symptoms involving lower GI tract include profuse watery 
diarrhea, crampy abdominal pain, bleeding and in most severe form paralytic ileus. 
Cholestatic jaundice (hyperbilirubinemia) is the most common manifestation of the liver 
involvement. As per Glucksberg or IBMTR scales each organ is given an individual stage and 
these stages are combined to overall grade of GVHD.  The overall grades are classified as I 
(mild), II (moderate), III (severe) and IV (very severe). 26 Only isolated skin aGVHD limited 
to a small surface area (stage I or II) can be treated with topical steroids. The standard primary 
therapy for grade II-IV acute GVHD are systemic corticosteroids (methylprednisolone 0.5 to 
2 mg/kg, depending on center). Concurrently, patients are continued on calcineurin inhibitor 
based GVHD prophylaxis. Systemic corticosteroids are lympholytic and rapidly inhibit the 
inflammatory cytokine cascade. The second line therapies in steroid refractory disease 
(progression after 3 days on corticosteroid therapy and no improvement after 5-7 days) 
include: sirolimus, mycophenolate mofetil, methotrexate, antithymocyte globulin, infliximab 
(anti-TNF alpha) and ECP. 27 An early response to corticosteroids is a significant predictor of 
outcome. The most established prognostic factors for poor survival and mortality are grade 
III-IV severity and refractory disease. 28,29 
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1.2.2. Chronic graft versus host disease (cGVHD)  
Chronic GVHD is a multisystem disorder and the leading cause of non-relapse morbidity and 
mortality in survivors after allo-HSCT, but it is also associated with lower malignancy relapse 
rate, presumably because of graft-versus-leukemia effects. 30,31,32 Chronic GVHD is the single 
major factor determining long-term outcome and quality of life after HCT. 33 The incidence of 
disease occurrence is approximately 50% of transplant recipients. 34 Patients with cGVHD 
have poor quality of life, impaired functional status, inability to work, and need for ongoing 
chronic care, which also has important impact to health-related costs. 35 
They often require prolonged immunosuppressive treatment for an average of 2-3 years, 
which than puts them in danger of infection and unwanted consequences of corticosteroid 
treatment. Typical clinical manifestations are very protean and may reflect active tissue 
inflammation such as erythematous rash, oral erythema and lichenoid changes as well as more 
chronic processes such as sclerotic skin changes, joint contractures or fasciitis of the 
subcutaneous tissue. 33 It may often appear similar to systemic autoimmune diseases such as 
systemic sclerosis or Sjogren’s syndrome. Despite recent progress in cGVHD severity staging 
36 there are no reliable clinical measures of disease activity to differentiate active 
inflammation from residual tissue damage. 
CGVHD Consensus Conference held in 2005 at the National Institutes of Health, USA, 
produced recommendations regarding cGVHD diagnosis, staging, histopathology, response 
criteria, biomarkers, ancillary and supportive care, and design of clinical trials.  
These recommendations provided scoring system based on number of organs involved, 
severity and functional disability. In 2014, second cGVHD NIH Consensus Conference 
updated these recommendations. 37 
Very recent study from the Center for International blood and marrow transplant research 
showed increasing incidence of cGVHD in last 12-year period. In the multivariate analysis the 
period from 2004-2007 was associated with higher risk of cGVHD when compared with the 
earlier time periods (1995-1999 and 2000-2003). In the multivariate analysis the use of bone 
marrow with an unrelated donor and PBSC graft with all categories of donor group was 
associated with higher risk of cGVHD as compared with use of bone marrow with a matched 
sibling donor. Also, patients who developed cGVHD, non-relapse mortality has decreased 
over time, but at 5 years there were no differences among different time periods. 38 
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1.2.2.1. Pathophysiology 
The pathophysiology of cGVHD remains unclear. The disease is characterized by a 
combination of allogeneic and auto-immune dysregulation with significant immune 
deficiency. Impaired responses by both T (Treg, Th1 and Th2) and B cells lead to cytokine 
and antibody production and inflammation.  39,40,41  In mouse model, Th1 cytokines (IL-2 and 
IFN-γ) can reduce cGVHD and Th2 cytokines such as IL-4, IL4, IL-5, IL-10, and IL-13 can 
increase cGVHD, 42 but mouse models do not replicate human cGVHD, which can be 
associated with either Th1 or Th2 cytokine imbalance supported by the results of various 
studies: Nakamura et al. showed that IL-4-producing CD8+ T-cells were was significantly 
higher in patients with cGVHD than in patients without cGVHD and may be an 
immunological hallmark of cGVHD 43; Ritchie et al showed that increased TNF-α and IFN-γ 
transcription predicted for the onset of extensive chronic GVHD 44, and Cavet et al showed 
that IFN-γ and IL-6 gene polymorphisms associate with cGVHD. 45 In cGVHD patients 
treated with ECP Th1 cells always increased during therapy, supporting the hypothesis that a 
more favorable immune balance contributes to clinical responses. 46 
Role of thymic regulation 
The immune reconstitution after HSCT is happening via thymic-independent (mature donor 
T-cells from the graft) and thymic-dependant pathway (production of naïve T cells from 
donor hematopoietic stem cell). 47,48 Tymic damage is caused both by conditioning regiment 
and acute GVHD. 49 Dysregulation of thymic function and failure of negative selection is 
certainly one of the causes of cGVHD. (Figure 3.)  CD4+ cells that express receptors with 
high affinity for "self-antigens" are normally deleted. CD4+ T cells generated de novo from 
donor stem cells appear to mediate the evolution of CGVHD from acute GVHD 50. In fact, 
cGVHD occurs, even though it may not be preceded by acute GVHD. Zhang et al. found that 
host thymus is not required for the induction of cGVHD and that quiescent autoreactive T and 
B cells in transplants from non-autoimmune donors might be activated and expanded to cause 
cGVHD with autoimmune manifestations. 51 
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T regulatory (CD4+CD25+) cells 
Treg cells are characterized by their constitutive expression of the IL-2 receptor α chain 
(CD25). A FOXP3, a member of forkhead family of transcription factors was shown to be 
highly expressed in Treg cells. In mouse models adoptive transfer of ex vivo expanded 
CD4+CD25+T cell can prevent GVHD. 52,53 In humans, studies results are controversial. 
Some studies have shown that patients with cGVHD  have elevated Tregs 54 and other 
reported decreased  Tregs numbers. 55,56 The mechanism by which Tregs suppress cGVHD 
remains uncertain, but there is evidence that suppression is mediated by cytokines, such as 
transforming growth factor TGF-β and interleukin IL-10, or by contact with plasmacytoid 
dendritic cells through indoleamine 2,3-dioxygenase. 57 The adoptive transfer of Tregs in 
animal models of GVHD has demonstrated their efficacy, which suggests that Tregs can be 
exploited in the clinical setting. 53 Giorgini et al. showed that alloantigen-driven expansion is 
critical for the effectiveness of Tregs, and suggested that cellular therapy with alloantigen-
induced Tregs in combination with glucocorticoids could prevent cGVHD after immune 
reconstitution. 58 Extracorporeal photopheresis increases levels of circulating functional Tregs 
in cGVHD patients 59 and recently, a novel photodepleting approach was found to both 
preserve and expand Treg numbers while selectively eliminating CD4+ effector T cells from 
patients with cGVHD. 60 
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Figure 3. Courtesy of Prof SZ PavleticFigure 3.   Immune dysregulation in cGVHD                              Courtesy of Prof SZ Pavletic         
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 cGVHD and autoimmunity 
On the other hand B-cell plays significant role in autoimmune component of cGVHD 
pathogenesis. Although cGVHD occurs in allogeneic transplant setting it shows some 
similarities with autoimmune diseases suggesting dysregulation in humoral immunity as well. 
It has been shown that patients with cGVHD have more circulating autoantibodies (anti-
nuclear, anti-mitochondrial, anti-smooth muscle, anti-parietal) 61,62 and higher levels of B cell 
activating factor (BAFF) in their sera. 63,64,65 As BAFF levels are high after allo-HSCT, B cells 
are not through negative selection are likely positively selected during B cell recovery. In a 
study performed by Patriarca et al it was shown that patients who developed autoantibodies 
showed faster B-cell recovery, based on significant increase of B cell subset.  
BAFF high levels and autoantibody production suggest a critical breakdown in peripheral B 
cell tolerance in patients with cGVHD and represents a model for aberrant persistence of allo- 
and auto-reactive B cells after transplantation and failure of normal B cell tolerance 
checkpoints. As a result, there is persistence of donor B cells reactive to recipient antigens 
and secretion of pathologic allo- and auto-antibodies. 66 
On the other hand these autoantibody positive patients showed abnormally low levels of 
serum immunoglobulins, which indicate, prolonged functional impairment. Also, donor B-cell 
responses to recipient HY antigens have been associated with the development of cGVHD in 
the setting of gender-mismatched alloHSCT. 67 This hypothesis is confirmed with anti-CD20 
monoclonal antibody successful treatment in steroid-refractory cGVHD. 68,69 It has been 
shown that cGVHD patients with hypergammaglobulinemia have a significantly increased 
BAFF/B-cell ratio and serum autoantibodies (ANA, anti-dsDNA) compared to patients with 
hypogammaglobulinemia. In addition, hypergammaglobulinemia was significantly associated 
with sclerodermous form of skin cGVHD in multivariate regression analysis. 65 It has been 
shown that antibodies to platelet-derived growth factor (PDGF) in patients with sclerotic 
cGVHD have the capacity to induce both tyrosine phosphorylation of the PDGF receptor and 
type I collagen gene expression in fibroblasts, leading to fibrosis. 63 
Moreover, B cells are essential in many functions other than antibody secretion; direct 
antigen-presentation with priming of T lymphocytes and secretion of cytokines that modulate 
the intensity and type of immune response. 70 Increased levels of TLR9 expression have been 
documented in B-cells from cGVHD patients, suggesting an improved ability of these cells to 
act as APCs and to sustain a chronic inflammatory environment. 71 
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Profibrotic-Inflammatory Cytokines  
Scleroderma-like changes in cGVHD occur in up to 13%–16% of patients. 72 Many 
similarities have been described between SSc and cGVHD. T-cells (CD4+) are necessary for 
the disease, but several lines of evidence point to a pivotal role of cytokines, mainly TGF-β, 
in the development of fibrotic changes. 73 
These observations initiated the treatment with a thyrosine-kinase inhibitors (in use for 
treatment of chronic myeloid leukemia) of PDGFR, c-KIT, BCR-ABL and share potent 
antifibrotic and anti-inflammatory properties, being powerful dual inhibitors of both PDGF-R 
and TGF-β pathways like imatinib with good responses in steroid refractory/dependent 
cGVHD. 74  
Spoerl et al showed that inhibition of JAK1/2 signaling resulted in reduced proliferation of 
effector T-cells and suppression of proinflammatory cytokine production in response to 
alloantigen in mice. They treated six treated patients with steroid-refractory GVHD with 
ruxolitinib. All patients responded with respect to clinical GVHD symptoms and serum levels 
of proinflammatory cytokines (suppression). Ruxolitinib impaired differentiation of CD4 (+) 
T cells into IFN-γ- and IL17A-producing cells, and promoted tolerogenic Treg cells. 75 
Role of eosinophils 
Increased peripheral blood eosinophils are known to be associated with cGVHD, i.e. a 
particular form of fasciitis, eosinophilic fasciitis, a scleroderma-like process in which the 
fascia is inflamed with eosinophilic infiltration. Results of a pilot study showed sparing effect 
of Montelukast (cysteinyl leukotriene receptor-1 antagonist) that targets eosinophils in 
treatment of cGVHD. 76 
Inflammatory response  
After activation, DC and B cells start to secrete inflammatory cytokines. As a marker of 
activated T cells, soluble interleukin-2 receptor alpha (sIL-2RL) has been reported to correlate 
with severity of aGVHD and cGVHD. 77 
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1.2.2.2. Risk factors 
Previous acute GVHD 
Chronic GVHD may be a later manifestation of alloreactive acute GVHD, a result of tissue 
damage caused by acute GVHD or treatment aimed to acute GVHD or share the same risk 
factors because both acute and chronic GVHD stem for alloreactivity.  
In a study performed by Flowers et al for all risk factors associated with cGVHD (use of 
female donors for male recipients, grafting with mobilized blood cells), point estimates and 
confidence intervals were not significantly changed after adjustment for prior acute GVHD 
that suggests the mechanisms involved in acute and chronic GVHD are not entirely congruent 
and that cGVHD is not simply the end stage of acute GVHD. 78 (Figure 4.) 
Peripheral blood stem cells as transplant source 
A meta analysis performed by Cutler et al showed that relative risk for development of 
cGVHD is much higher after peripheral blood than bone marrow transplantation. 79 The 
underlying immunologic factors affecting the appearance of cGVHD in peripheral blood and 
bone marrow recipients are not completely understood. High CD34+ counts may be important 
factor, since cGVHD did not correlate with CD3+ counts. Higher doses of CD34+ cells (> 8.0 
x106/kg) were associated with significantly increased risk of clinical extensive cGVHD. 80  
HLA disparity between recipient and donor 
Chronic GVHD occurs in approximately one-third of patients receiving HLA-identical sibling 
transplants, half of patients undergoing HLA non-identical related HSCT, and two-thirds of 
those undergoing matched unrelated HCT. 31,34 Minor HLA antigen mismatches are also 
recognized in the development of cGVHD when a male recipient receives cells from female 
donor, especially when donor had prior pregnancy or transfusions. Miklos et al showed that 
antibody responses to H-Y minor histocompatibility antigens correlate with cGVHD. 67 
 
Age of the recipient and donor 
Adult transplant recipients develop cGVHD more often (46%) than pediatric patients (13%). 
Allo-HSCT after RIC in high-risk patients (older age) also resulted in high incidence of 
cGVHD. Older donor age (more than 30 years old) is associated with increased risk of 
cGVHD development. 33,78,34 
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Infection 
Some reports link cytomegalovirus (CMV) infection with chronic GVHD. CD13 is aberrantly 
expressed in CMV-infected individuals, and antibodies to CD13 have been associated with 
chronic GVHD. 81,82 
 
  
Figure4. Multivariate risk factor profiles for grades 2-4 acute GVHD and NIH cGVHD 
Hazard ratio and 95% CI for each risk factor 78 
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Thrombocytopenia 
A low platelet count in cGVHD patients is among the most consistent and strongest negative 
survival predictors across cGVHD studies in both allogeneic bone marrow transplantation 
(allo-BMT) and allogeneic peripheral stem cell transplantation (allo-PBSCT). 83–85,86–91 
Patients with cGVHD and persistent thrombocytopenia demonstrate poorer responses to 
therapy, experience higher mortality rates from infection or, less often, from hemorrhage. 86,92 
Low platelet counts were also reported as a marker for a group of patients with severe 
cGVHD who have increased incidence of transplant-related complications and a higher 
mortality rate. 84–86,90,92,93,94,95 The thrombocytopenia in cGVHD is not usually associated with 
disease relapse or graft rejection, but significantly correlates with increased non-relapse 
mortality, 96 indicating the existence of additional poorly understood pathophysiological 
mechanisms that could generate the association of thrombocytopenia and negative outcome of 
cGVHD.  
Although thrombocytopenia in cGVHD patients is strong predictor of poor survival in many 
cGVHD studies, such correlation is still neither clearly explained nor well understood. 
Several possible mechanisms of thrombocytopenia in the cGVHD setting were proposed: 
transplant-related thrombocytopenia, malignancy relapse, microangiopatic thrombocytopenia, 
drug-induced thrombocytopenia, immune-mediated thrombocytopenia, hypersplenism, 
infection, cytokine-induced thrombocytopenia (increased TGF-β, low thrombopoietin level, 
other cytokines). 83 
 
Type of onset 
Chronic GVHD that evolves directly from aGVHD; progressive-onset has worse prognosis 
than quiescent or de novo onset.  
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1.2.2.3. Survival  
Recent study by Arora et. al showed that in the multiple regression model, increasing 
recipient age, the presence of and higher grade of prior aGVHD, early onset of cGVHD (< 5 
months), higher serum bilirubin at cGVHD onset, lower Karnofsky performance status at 
cGVHD onset, presence of thrombocytopenia at cGVHD onset (platelet count of < 
100x109/L), transplantation from a mismatched URD or other related donor versus an HLA-
identical sibling donor, disease status at transplantation (intermediate or advanced versus 
early), GVHD prophylaxis, and gender mismatch (female donor to male recipient versus male 
donor to male recipient) were significantly associated with a higher risk of mortality. 97 
Factors associated with a decreased risk of NIH chronic GVHD were the use of rabbit ATG in 
the pretransplant conditioning regimen and a diagnosis of CML. 98,34
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1.2.2.4. Diagnosis 
Diagnosis of cGVHD is made based on established NIH Consensus criteria 16 and requires the 
following: distinction from acute GVHD, the presence of at least one diagnostic feature such 
as skin or oral mucosa lichen planus-like changes, poikiloderma, deep sclerotic features of 
chronic GVHD (Table 2.) or the presence of at least one distinctive clinical manifestation 
confirmed by biopsy or laboratory tests, (evaluation by ophthalmologist, gynecologist) or 
radiology (Table 3.) and exclusion of other possible diagnoses. 
Table 2. Diagnostic cGVHD features 
Diagnostic features of 
cGVHD   
Skin  Poikiloderma 
  Lichen planus-like  
  Morphea-like  
  
Lichen sclerosus-like  
Deep sclerotic features 
Mouth  Lichen-type 
  Hyperkeratotic plaques 
  
Restriction of mouth opening from 
sclerosis 
Genitalia Lichen planus-like  
  Vaginal scarring 
Gastrointestinal tract Esophageal web 
  Strictures or stenosis in the  
  upper to mid third of the esophagus 
 
Lung 
 
Bronchiolitis obliterans  
  diagnosed with lung biopsy 
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Fascia, Joints Fasciits 
  
Joint stiffness or contractures 
secondary  
  to sclerosis 
 
 
Table 3. Distinctive cGVHD features 
Distinctive features of 
cGVHD   
Skin  Depigmentation 
Nails   Dystrophy 
 Longitudinal ridging, splitting or brittle features 
 Pterygium unguis 
 Nail loss (symetric; affects most nails) 
Scalp and body hair 
New onset of scarring or nonscarring scalp alopecia (after 
recovery from chemotherapy) 
 Scaling, papulosquamous lesions 
Mouth  Xerostomia 
  Mucocele 
  Mucosal atrophy 
 Pseudomembrane 
 Ulcers 
Genitalia Erosions  
  Fissures 
 Ulcers 
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Eyes Cicatrical conjunctivitis 
  New-onset dry, grity, or  
  Keratoconjuntivitis sicca 
 Confluent areas of punctate keratopathy 
Lung Bronchiolitis obliterans  
  diagnosed with PFTs and radiology 
Muscles, joints, fascia, Myositis or polymyositis 
 
 
1.2.2.5. Classification 
Classic: presence of at least one diagnostic or distinctive manifestation of cGVHD without 
features characteristic of acute GVHD. 
Overlap: presents at any time post-HCT with features of both chronic GVHD and acute 
GVHD. 
1.2.2.6. Onset 
De novo: no prior aGVHD 
Quiescent: prior aGVHD with resolution 
Progressive: onset of chronic GVHD without resolution of prior existing acute GVHD with 
inferior overall survival. 99 
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1.2.2.7. Staging  
Global cGVHD scoring  
Mild cGVHD involves only 1 or 2 organs or sites (except the lung), with no clinically 
significant functional impairment (maximum of score 1 in all affected organs or sites).  
Moderate cGVHD involves (a) at least 1 organ or site with clinically significant but no major 
disability (maximum score of 2 in any affected organ or site) or (b) 3 or more organs or sites 
with no clinically significant functional impairment (maximum score of 1 in all affected 
organs or sites). A lung score of 1 is also moderate cGVHD.  
Severe cGVHD indicates major disability caused by cGVHD (score of 3 in any organ or site). 
A lung score of 2 or greater is also severe cGVHD. 16 (NIH score sheet- Figure 5.) 
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* AP may be elevated in growing children, and not reflective of liver dysfunction 
Other indicators, clinical manifestations or complications related to cGVHD (check all that apply and assign a 
score to its severity (0-3) based on its functional impact (none – 0,mild -1, moderate -2, severe – 3) 
 Esophageal stricture or web___  Pericardial Effusion___   Pleural Effusion(s)___ 
 Ascites (serositis)___  Nephrotic syndrome___   Peripheral Neuropathy___ 
Myasthenia Gravis___  Cardiomyopathy___   Eosinophilia > 500μl___ 
 Polymyositis___                 Cardiac conduction defects___  Coronary artery involvement___ 
 Platelets <100,000/μl ___  Progressive onset 
 OTHERS: _________ 
 
Figure 5. cGVHD score sheet 
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1.2.2.8. Clinical manifestations 
Skin: Diagnostic signs for skin cGVHD include lichen planus-like eruption (plaques with a 
silvery or shiny appearance), poikiloderma, morphea-like superficial sclerotic features 
(localized patchy areas) or lichen sclerosus-like lesions (discrete gray to white moveable 
papules plaques), deep sclerotic features ("thickened or tight skin", caused by deep and 
diffuse sclerosis over a wide area) (Figure 6.).  
Mouth: Lichen planus-like changes (white lines and lacy-appearing lesions of the palate, 
buccal mucosa or lips), hyperkeratotic plaques, or decreased mouth opening because of the 
sclerotic features of the skin cGVHD. 
Genital tract in women: Vaginal scarring or stenosis and lichen planus-like changes.  
Lung: clinical manifestations include dyspnea on exertion, cough, or wheezing. The only 
diagnostic sign is biopsy proven bronchiolitis obliterans. BO is clinically diagnosed if 1) 
FEV1/FVC ratio <0.7 and FEV1 <75% of predicted. 2) Evidence of air trapping or small 
airway thickening or bronchiectasis on high-resolution chest computed tomography (with 
inspiratory and expiratory cuts), residual volume (RV) >120%, or pathologic confirmation of 
constrictive bronchiolitis. 3) Absence of infection in the respiratory tract, documented with 
investigations directed by clinical symptoms, such as radiologic studies (radiographs or 
computed tomographic scans) or microbiologic cultures.  
Muscles, joints and fascia: Joint stiffness, fasciitis or contractures due to sclerosis.  
Gastrointestinal tract: Esophageal web, stricture or concentric rings documented by 
endoscopy.  
Eyes: Diagnostic signs (diagnosed by ophtalmologist) include cicatrial conjunctivitis, 
keratoconjunctivitis sicca and punctate keratopathy.  
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Figure 6.    Spectrum of manifestations in cGVHD              Courtesy of Prof SZ Pavletic 
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1.2.2.9. Prevention 
Although many recipient risk factors associated with increased cGVHD are not modifiable, 
and include older age, underlying diagnosis, lack of an HLA-matched donor, while other 
modifiable factors are associated with lower incidence of cGVHD such as choosing a better 
donor (male, younger), use of bone marrow rather than peripheral blood, 100 and limitation of 
CD34+ and T-cell dose 80 infused may reduce the risk of cGVHD. If the recipient is male, 
then avoidance of a female donor, especially someone multiparous, may decrease the risk of 
chronic GVHD. Donor ABO compatibility and CMV seronegativity have also been 
associated with lower risks of cGVHD. While umbilical cord blood is currently a graft source 
of last resort in adults, it appears to be associated with lower rates of chronic GVHD. 101 
Prophylaxis by combined immunosuppression 
Various combined regimens (cyclosporine+methotrexate, cyclosporine+mofetil-
micophenolate, prednisone +tacrolimus, etc.) have been used for cGVHD prevention but none 
of them is highly effective.   
Prophylaxis by T-cell depletion  
Ex vivo: Methods of T-cell depletion include the use a single monoclonal antibody targeting 
several cell subpopulations (e.g. alemtuzumab), or selective removal of T, B, and NK-cells, as 
well as positive selection of CD34 or CD133 progenitors. 102,33 Because poor immune 
reconstitution after TCD grafts and relapse (GVL effect), the prevention of GVHD does not 
mean better outcome, on the contrast overall and leukemia free survival has been inferior 
comparing to patients receiving unmanipulated transplants. 103 
In vivo: In vivo T-cell depletion (as part of the preparative regiments) with antibodies (rabbit 
or horse ATG, alemtuzumab) administration prevents GVHD by targeting and down 
regulating incoming donor T-cells and reduces the host immune response in favor of 
engraftment. In vivo T-cell depletion is successful in aGVHD prevention but results in 
cGVHD prevention are less evident, 104 except in a study by Finke et al. where it was shown 
that addition of ATG to GVHD prophylaxis with cyclosporine and methotrexate resulted in 
decreased incidence of acute and chronic GVHD without an increase in relapse, non-relapse 
mortality or infection rate. 105 
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1.2.2.10. Treatment 
Treatment of the chronic GVHD requires multidisciplinary approach. Patients require joint 
care of specialists’ team including dermatology, dental, ophthalmology, gynecology, physical 
medicine etc.  
a) systemic therapy: immunosuppressive or immunomodulatory agents 
 b) topical and symptomatic therapy 
c) supportive care 
a) Systemic therapy 
First-line:  
The mainstay of cGVHD treatment is systemic therapy. First-line treatment of chronic GVHD 
consists of steroids alone or in combination with calcineurin inhibitors and is based on 
randomized trials. 106 The recommended dose of steroids (prednisone or methylprednisolone) 
is 1 mg/kg/day. The generally recommended approach involves continued administration of 
the calcineurin inhibitor used for GVHD prophylaxis together with prednisone initially at 1 
mg/kg/day. The combination of steroids with calcineurin inhibitors (cyclosporine or 
tacrolimus) is particularly indicated in treatment of moderate or severe cGVHD or for those 
with less severe disease but with high-risk features (thrombocytopenia <100, progressive 
onset or bilirubin >2 mg/dl at onset).  34 Combination use of cyclosporine and prednisone 
confirmed, however, beneficial steroid sparing effects of cyclosporine as demonstrated by 
lower incidence of avascular bone necrosis in patients in the combination arm. 107 
For mild cGVHD case the use of topical immunosuppressant (topical calcineurin inhibitors, 
topical steroids, phototherapy) for oral mucosa, eye and skin. 
Response should be assessed not before eight weeks of treatment have been finished, or until 
up to 3-6 months of treatment have been finished in the case of deep skin sclerosis. Strategies 
for the tapering the dose of prednisone vary, but as a general preference, one should use the 
minimum dose that is sufficient to control cGVHD manifestations. First line treatment 
achieves remission in approximately 20% of adult and 50% of pediatric patients. 108 
Currently, no uniformly accepted definition of steroid refractory cGVHD is available. 
Generally, accepted criteria for steroid refractory cGVHD are (1) progression despite 
immunosuppressive treatment using 1 mg/kg/day of prednisone for 2 weeks, (2) stable disease 
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if 4 to 8 weeks on ≥0.5 mg/kg/day of prednisone, and (3) inability to taper below 0.5 
mg/kg/day of prednisone. 106 
Second-line: 
In case of first-line steroid-based therapy failure due to progression or refractory disease, 
second line treatment is indicated. The list of drugs for salvage therapy is long (Table 4.), 
there is no standard treatment, and trial-and-error remains the major way to identify an 
effective treatment of the individual. 34 Response rates vary from 25-75% (photopheresis) and 
these responses are most commonly incomplete or not durable. 23,109 Polypharmacy is 
common in cGVHD patients, but no more than three immunosuppressive agents shod be 
given, as combination of more drugs does not lead to improvement but leads to increased risk 
of toxicity and infections. 108 
The median duration of treatment is approximately 2 years in patients who had HCT with 
marrow cells and 3.5 years in those who had HCT with peripheral blood stem cells. 110 
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Table 4. List of 30 agents used in secondary therapy 111 
 
• Acitretin/etretinate 
• Alefacept 
• Alemtuzumab 
• Antithymocyte globulin 
• Azathioprine 
• Bortezomib 
• Clofazimine 
• Daclizumab 
• Extracorporeal photopheresis (ECP) 
• Etanercept 
• Halofuginone 
• Imatinib 
• Infliximab 
• Interleukin-2 
• Lidocaine 
• Mesenchymal stem cells (MSC) 
• Methotrexate 
• Montelukast 
• Mycophenolate mofetil 
• Pentostatin 
• Pravastatin 
• Psoralen/UVA 
• Rituximab 
• Sirolimus 
• Steroids (pulse) 
• Thoraco-abdominal radiation 
• T-regulatory cell infusions 
• Thalidomide 
• Ursodeoxycholic acid 
• UVB 
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b) Topical and symptomatic therapy 
Topical therapy includes corticosteroids, calcineurin inhibitors, PUVA for skin or mouth, and 
topical estrogens, corticosteroids, calcineurin inhibitors for gynecological manifestations.  
c) Supportive and ancillary care 
Prolonged immunosuppressive therapy including steroids is often necessary to control disease 
manifestations and severity. Treatment, combined with delayed and impaired immune 
reconstitution associated with cGVHD, increases the risk of infections and other 
complications. Clinical manifestations of cGVHD can persist for prolonged periods of time, 
causing significant morbidity. Some of these changes, such as contractors, may be 
irreversible. Infection is the most common cause of mortality in patients with cGVHD, and 
prophylaxis of infections requires special focus. The immune defects in cGVHD are broad, 
including macrophage function, antibody production, and T-cell function. All patients with 
cGVHD are considered at risk for infection with encapsulated bacteria, particularly 
Streptococcus pneumoniae. Prophylactic antibiotics (penicillin V K) should be given to all 
patients with cGVHD during immunosuppressive treatment. Most experts recommend 
Haemophilus influenzae B conjugate or influenza vaccinations, since the risk of adverse 
outcomes is low. No live viruses should be given. IVIg should be considered for patients who 
have recurrent infections and IgG levels less than 400 mg/dl. Invasive mould infections are 
also one of the major concerns in patients under immunosuppressive treatment, and antifungal 
therapy is also necessary, especially when the corticosteroid dosage is more than 0.5-1.0 
mg/kg/day. All patients should receive Pneumocystis carinii prophylaxis (trimethoprim-
sulfamethoxazole, which also ensures prophylaxis against Toxoplasma and Nocardia). Some 
centers use long-term antiviral prophylaxis to prevent recurrent herpes simplex and varicella 
zoster virus infection. Cytomegalovirus (CMV) disease monitoring after day 100 is 
recommended in patients with active cGVHD, history of CMV reactivation and lymphopenia. 
Monitoring, surveillance for malignances and management of medication toxicities (e.g. 
hypertension, renal dysfunction etc) is necessary. Organ specific interventions include: for 
skin photoprotection, topical emollients, antipruritic agents, topical corticosteroids; for eyes 
photoprotection, artificial tears, contacts lens, ointments, topical steroids, topical 
cyclosporine, punctual occlusion, autologous eye drops, surveillance for cataract and 
infection; for mouth oral  hygiene, topical steroids or topical calcineurin inhibitors, topical 
analgesics, surveillance for malignancy and infection; for lungs bronchodilatators, pulmonary 
rehabilitation, oxygen, surveillance for infection; for gynecological tract in women topical 
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estrogens, topical calcineurin inhibitors, topical steroids, vaginal dilatators, surveillance for 
infection (HPV, HSV) and malignances; for musculoskeletal system physical therapy, bone 
densitometry, therapy for osteopenia or osteoporosis, surveillance for decreased range of 
motion; for neurologic system treatment of neuropathic syndromes, calcineurin levels 
monitoring, seizure prophylaxis, blood pressure control, EMNG monitoring. 
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1.2.2.11. Biologic markers of chronic GVHD 
Lots of studies are published and trying to identify cGVHD biomarker that could provide 
clinically useful information (correlation with development, diagnosis and prognosis of 
disease). An ideal biomarker should be highly sensitive and specific, reflecting the current 
status of disease; should be related to the disease activity and/or severity in accordance with 
the clinical evolution; should anticipate clinical changes before they occur; and should add 
independent information about the risk or prognosis that is reproducible and feasible. The 
NIH definition of a biomarker is a characteristic that is objectively measured and evaluated as 
an indicator of normal biologic processes, pathogenic processes or pharmacologic response to 
a therapeutic intervention. 112 
The disease is a result of a Th1 and Th2 impaired function. There are data suggesting that 
development of cGVHD may be a Th2-mediated process, because of the increased production 
of IL-4, IL-5, IL-10 cytokines. 113 A group of investigators identified an IL-10 promoter gene 
polymorphism known to be associated with a lower production of IL-10 correlated with 
cGVHD development and another that higher levels of IL-10 at the fourth month post-
transplant is associated with development of cGVHD due to Th2 predominance. 114,40 High 
levels of Th1 cytokines (IL-1, TNF-α, INF-γ) have been found in  the sera of cGVHD patients 
39, in contrast to low levels of INF-γ described by another group.  
Various studies suggested that risk for cGVHD development may be associated with donor-
recipient genetic polymorphism, deficiency in regulatory immune cell populations (NK, Treg, 
DC2), and variation in inflammatory and immunoregulatory mediators post-alloHSCT 
(increased TNF-α, IL-10 and BAFF, and decreased TGF-β and IL-15). CGVHD is associated 
with alteration in immune cell populations (increased CD3+ T cells, Th17, CD4+ and CD8+ 
effector memory cells, monocytes, CD86 expression, BAFF/B cell ratio, and deficiency of 
Treg, NK cells, and naïve CD8+ T cells). 115 
Most studies support increased pro-inflammatory cytokines in chronic GVHD cases, 
including TNF-, IL-6, IL-1β, IL-8, sIL-2R, and IL-1Ra. Validated proteomic work from 
suggests that BAFF, sCD13, elafin, IL-2Rα, MIG (CXCL9), and anti-dsDNA may distinguish 
cGVHD cases from non-chronic GVHD controls with high accuracy. 115 
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1.3. Inflammation and acute phase reactants 
1.3.1. Inflammation 
Inflammation is a complex organism response to biological, chemical or physical insult. In 
the acute phase, leukocytes, primarily granulocytes, migrate along a chemotactic gradient to 
the site of injury in a carefully orchestrated effort that is mediated by cytokines and acute 
phase reactants to remove the stimulus or cells damaged by injury and to initiate healing. 
Persistent inflammation as a result of prolonged exposure to stimulus or an inappropriate 
reaction to self molecules can lead to the chronic phase in which the active immune cell 
populations shift to include a mononuclear phenotype, and tissue damage and fibrosis can 
occur. Chronic inflammation is reported to contribute to numerous diseases including allergy, 
arthritis, asthma, atherosclerosis, autoimmune diseases, diabetes, and cancer, and to 
conditions of aging. The inflammatory process involves multiple physiological systems with 
the immune system playing a central role. In the acute phase, platelets and granulocytic cells 
such as basophils/mast cells, neutrophils and eosinophils are activated; producing and 
releasing a number of soluble mediators that stimulate and regulate the inflammatory 
response.  
Acute-phase responses (APR) are systemic reactions that reflect organ site inflammation in 
acute and chronic diseases. 116 It is characterized by increased plasma concentration of acute 
phase proteins driven by various cytokines release. Major acute phase proteins include: 
transport proteins (ceruloplasmin, haptoglobin), complement system (C3, C4, C5), 
coagulation system (fibrinogen, vWF, plasminogen and antithrombin III) and other (CRP, 
serum amyloid A, ferritin, IL-1RA and α2-macroglobulin) 117,116. Many cytokines and 
chemokines contribute to inflammation; some facilitate leukocyte chemotaxis to the site of 
injury, while others modulate immune cell function. The cytokines that are best known for 
stimulating and perpetuating inflammatory responses are IL-6, IL-1, IL-2, TNF-α, IFN-γ, and 
transforming growth factor (TGF)-β. IL-6 was originally identified as a B-cell differentiation 
factor, and increased levels of this cytokine have been associated with polyclonal B cell 
activation and chronic inflammation. In the initial phases of acute inflammation, IL-6 
mediates the acute phase response. IL-6 levels remain high in chronic inflammatory processes 
leading to enhanced survival and growth of lymphocytes and macrophages that perpetuate 
inflammation. IL-1 has a number of direct and indirect activities that promote inflammation 
including the stimulation of the production of other cytokines and the release of 
prostaglandins. These promote the generation of cytotoxic effector cells and synergize with 
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colony stimulating factors to increase the production of inflammatory cells in the bone 
marrow. IL-2 augments NK cell activity, stimulates the production of inflammatory cytokines 
such as IL-1 and IFN-γ and enhances macrophage cytotoxicity. It also contributes to chronic 
inflammation by stimulating the proliferation of antigen specific T- and B-lymphocytes. TNF-
α enhances inflammation and is important in the process of removing dead and dying cells 
through apoptosis. TNF- α has been shown to upregulate the expression of Class I and II 
major histocompatibility complex (MHC) molecules on certain cell types resulting in cell 
activation and cytokine release. IFN-γ is a potent activator of macrophages. It stimulates the 
production of IL-1 and TNF-α and enhances the expression of Class II MHC molecules on 
immune cells and vascular endothelium. The latter is of particular importance in allowing 
inflammatory cells to move through the vasculature into tissues or a site of injury. TGF-β is 
important in the regulation of tissue repair and regeneration following injury. It is produced 
by a number of immune and nonimmune cell types and is important in the regulation of the 
inflammatory response by inhibiting the production of proinflammatory cytokines such as IL-
2, IFN-γ. 
Cytokines responsible for synthesis of APR in hepatocytes are: TNF-α, IL-1β, INF-γ, TGF-β 
and particularly IL-6 produced by macrophages and monocytes. 118 Serum levels of IL-6 and 
CRP often correlate. These cytokines suppress the synthesis of albumin. Hypoalbuminemia is 
a frequent during inflammation. 119 Despite it is called acute phase reactant its level can and 
often is increased and used for disease activity monitoring in chronic inflammatory states and 
autoimmune diseases such as rheumatoid arthritis. 117,120 They are also called "positive acute 
phase proteins" because their concentration in serum increases during inflammatory state. 
There are also "negative acute phase proteins" like albumin, transferin and transthyretin 
whose synthesis during inflammation is decreased (Figure 7.). 
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Figure 7. Acute phase reactants whose concentration increases or decreases during 
inflammation
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1.3.2. C-reactive protein (CRP)  
CRP is a beta globulin and it is the best known acute phase serum protein which is widely 
used as marker of infection and intensity of inflammatory process. It has proinflammatory as 
well as anti-inflammatory effects. Proinflammatory effects include ability to activate classical 
complement cascade, which is different from activation by antibody, binding to FcγRI and 
FcγRII on the surface of leucocytes, which activates them. Anti-inflammatory effects include 
binding to apoptotic and necrotic cells thus facilitating opsonisation and phagocytosis by 
macrophages. 121,122 A very important property of CRP is the ability to bind C1q to activate 
the classical complement cascade and enhancing the capacity for defense against stimuli. CRP 
is absent or present in very low concentrations in normal serum. Many studies demonstrate 
that normal CRP levels in the American population are less than 2 or 3 mg/L. 123,124 Minor 
CRP elevation (3-10 mg/L) has been regarded as a marker of "low grade inflammation". 
Values greater than 10 mg/L are generally accepted to be regarded as reflecting clinically 
significant inflammation. 124,125,126 On the contrary markedly elevated levels of CRP are 
strongly associated with infection. 127  
Low grade inflammation differs from acute inflammation. It is usually associated with some 
chronic condition in which classic clinical signs of inflammation are missing. Also lots of 
data from the epidemiological studies had shown positive correlation between minor CRP 
elevation and underlying atherosclerosis, metabolic syndrome and risk of cardiovascular 
events as well as conditions including obesity, type 2 diabetes, asthma and neurodegenerative 
diseases — are all characterized by chronic low-grade inflammation. 128,129,130  
Patients with cGVHD have enhanced expression of the inflammatory cytokines TNF-α, IL-6, 
TGF-β, IL-1β and IFN-γ and decreased levels of anti-inflammatory cytokines such as IL-10, 
as is seen in APR. 39,62,116,131,132,133,134 A number of acute phase reactants have well established 
roles in monitoring clinical outcomes for systemic inflammatory and autoimmune diseases. 
116, 135 CRP (C-reactive protein) and erythrocyte sedimentation rate (ESR) correlate with 
activity of rheumatoid arthritis.14 CRP has also been shown elevated in 46% of SSc patients. 
136 This is in contrast to systemic lupus erythematosus in which CRP values are typically 
normal or only modestly elevated and decreased levels of complement components C3 and 
C4 are associated with active disease. 137,126 Therefore, it is essential to validate these tests in 
individual disease settings.   
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Increased levels of CRP are strongly associated with major transplant-related complications 
like veno-occlusive disease (VOD) and acute GVHD. 138,139 Also conditioning with TBI was 
associated with significantly elevated levels of CRP. 138,139  
1.3.3. Complement system  
Complement system is organized system of serum proteins and important part of antigen-
nonspecific part of the immune response. The complement system is a complex network of 
proteins that participate in the acute inflammatory response through their enzymatic activity, 
effects on mediator release, chemotaxis and vascular permeability, and the ability to enhance 
phagocytosis through opsonization of microbes. C3 and C4 are acute phase proteins and their 
levels increase in acute phase response. Complement levels are usually normal or decreased in 
autoimmune diseases. C3 and C4 are proteins whose plasma concentration increases in terms 
of inflammation. 116 
1.3.4. Ferritin  
Ferritin concentration in plasma is an indicator for organism iron stores. Though an elevated 
ferritin level is used as surogate for iron stores, it may be elevated in other circumstances, 
including inflammation and may also occur in association with abnormal liver function tests 
and longer disease duration. Ferritin is an acute phase reactant which concentration rises in 
acute phase reaction under influence of cytokines such as IL-1 and TNF. 140 Also, ferritin has 
been incorporated into prognostic scoring systems for patients undergoing myeloablative 
allogeneic transplantation for acute leukemia and MDS. 141 Iron overload is known to have an 
immunomodulatory effect, influences innate and acquired immune responses. Reduced CD8+ 
T-cell counts have been observed in patients with iron overload caused by thalassaemia or 
haemochromatosis. 142  Several studies have reported the association between iron overload 
and transplant related complications such as sinusoidal obstruction syndrome, infection and 
idiopathic pneumonia syndrome. 143 In a few case reports, hemosiderin deposits were 
described in cGVHD related myopathy. 144 Beside that hyperferritinemia is associated with 
lower incidence of cGVHD, high relapse rate and decreased survival. 145,146  
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1.3.5. Albumin 
Albumin is quantitatively the most important protein. Albumin synthesis is regulated by 
cytokines, hormones, nutritional status and serum oncotic pressure. 147 Hypoalbuminemia is a 
reflection of hepatic synthesis dysfunction and lots of other conditions such as a malnutrition, 
nephrotic syndrome and inflammation. Albumins are negative phase reactants. Their levels 
are falling during the inflammation. 119 
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2. Hypotheses  
Inadequate or increased production of proinflammatory cytokines is associated with chronic 
GVHD.  Their production are usually increased in active and severe cGVHD and decreased in 
inactive and moderate cGVHD. The proinflammatory cytokines can lead to increased or 
decreased (depending on function) synthesis of acute phase reactants. So the acute phase 
reactants of inflammation are expected to be increased in active or severe cGVHD and lower 
in inactive or moderate cGVHD. If it is so, these acute phase reactants - laboratory markers of 
inflammation can serve as indicators of activity and severity of cGVHD.  They also could be 
a valuable indicator of treatment response and follow-up after treatment of cGVHD.  
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3. Aims and purpose of the research 
Aims 
1. To determine the level of laboratory markers of inflammation (routinely measured 
in clinical practice) in cGVHD in relation to disease activity and severity 
 2. To identify clinical and biological markers of cGVHD activity  
 3. To identify laboratory indicators of inflammation predictive for prognosis and 
 survival 
Purpose and expected scientific contribution of the research 
As there are no standard measures to define activity of cGVHD, this research would pioneer 
the identification, and possible clinical implementation of laboratory markers of inflammation 
relevant to the disease activity assessment, with the goal of early treatment and prevention of 
irreversible organ damage, as well as disease monitoring and treatment response. 
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4. Patients, methods and plan of investigation 
4.1. Patients 
The research was done at the Experimental Transplantation and Immunology Branch, 
National Cancer Institute, National Institutes of Health in Bethesda, MD, USA in 
collaboration with Division of Hematology, Department of Internal Medicine of School of 
Medicine, University of Zagreb, within a protocol "Leukemias and hematopoietic stem cell 
transplantation".  
The research included 189 adult patients median 48 years old [18-70] who were enrolled in 
the National Cancer Institute protocol "Natural History Study of Clinical and Biological 
Factors Determining Outcomes in Chronic Graft-Versus-Host Disease".   
4.2. Methods 
4.2.1. Plan of investigation 
Research plan 
1. To determine distributions profiles for markers of inflammation of interest in this 
cGVHD population. 
2. To determine in univariate and multivariate analysis whether there is any statistically 
significant correlation between these biomarkers and cGVHD study endpoints and 
investigate their role in the context of other clinical parameters. Multivariate analysis 
will be done adjusted for the time post transplant. 
Investigate in a preliminary fashion if there are any statistical differences between laboratory 
markers of inflammation and control values in patients without chronic GVHD. 
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All patients included into the study underwent a four-day, one-time visit evaluation by a 
multi-disciplinary team that included experts in dermatology, ophthalmology, dentistry, 
rehabilitation medicine, gynecology, pain and palliative, and hematopoietic cell 
transplantation. Patient evaluation also included comprehensive history and physical 
examination, functional measurements and quality of life (QOL) assessments. In addition, 
patients also undergo extensive sub-specialist evaluation with in-depth subspecialty grading 
of the key organs, such as the Schubert Scale for oral involvement, Schirmer’s tear test and 
eye exam, and NIH Skin Response Scale. Clinical assessments and laboratory data were 
recorded at the time of the visit using the pre-defined data collection forms that included NIH 
score sheet, Clinician activity assessment (form A, Figure 9. A), patient report form (form B, 
Figure 9. B) and subspecialists evaluations forms. For all patients laboratory assessment have 
been performed: complete blood count, platelets, CRP, ESR, C3, C4, total complement, IgA, 
IgG, IgM, total proteins, albumin, beta-2 microglobulin, ferritin and parathyreoid hormone.  
 
Research plan is given in Figure 8.   
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Figure 8. Research plan 
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 A. Form A 
Today’s Date: ______________      Patient Name: ________________  Current Weight: ___________________ 
 
CHRONIC GVHD ACTIVITY ASSESSMENT- CLINICIAN 
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B. Form B 
Symptoms Not 
present          
As bad as 
you can 
imagine 
Symptoms have been in 
the last seven days.  
Please fill in the circle 
below from 0 (symptom 
has not been present) to 
10 (the symptom was as 
bad as you can imagine it 
could be) for each item. 
0 1 2 3 4 5 6 7 8 9 10 
Your skin itching at its 
WORST? 
          
Your mouth dryness at its 
WORST? 
          
Your mouth pain at its 
WORST? 
          
Your mouth sensitivity at 
its WORST? 
          
Eyes                                        What is your main complaint with regard to your eyes?
 Please rate how severe is this eye symptom, between 0 (not at all severe)  and 
10 (most severe): 
0    1    2    3    4    5    6   7    8    9    10
Vulvovaginal Symptom 
(females only) 
Do you have any burning, pain or discomfort in the area of your vagina, vulva 
or labia?   
OR 
Do you have any discomfort or pain with sexual intercourse? 
o Yes 
o No 
o Not applicable 
Patient Global Ratings: 
1. Overall, do you think that your chronic graft versus host disease is mild, moderate or severe? 
1= mild 
2=moderate 
3=severe 
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2. Please circle the number indicating how severe your chronic graft versus host disease symptoms are, where 0 is cGVHD symptoms that are not at 
all severe and 10 is the most severe chronic GVHD symptoms possible. 
 
          0         1           2           3           4           5           6           7           8            9           10 
cGVHD symptoms                                                                                                                                      Most severe cGVHD                                                         
not at all severe                                                                                                                                           symptoms  possible                                                            
 
3. Compared to a month ago, overall would you say that your cGVHD symptoms are: 
 
+3= Very much better 
+2= Moderately better 
+1=A little better 
 0= About the same 
-1=A little worse 
-2=Moderately worse 
-3=Very much worse 
 
 
Figure 9. A. Form A; B. Form B 
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4.2.2. Exclusion of infection  
To exclude the infection in patients with elevated CRP (>0.8 mg/dL) the following laboratory 
and clinical assessment have been performed:  
- Infectious disease consult  
- Microbiology assessment: specify urine and blood cultures, swabs, CT scan of the 
sinuses, PCR CMV and EBV DNA  
Patients who received allogeneic hematopoietic stem cell transplant at the NIH without 
cGVHD served as the age and sex matched controls (N=17) for this study. All subjects signed 
NCI IRB approved informed consent.  
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4.2.3. Chronic GVHD definition criteria  
4.2.3.1. Chronic GVHD activity: 
Chronic GVHD activity was defined by:  
a) Intensity of systemic immunosuppression at the time of evaluation:  None, Mild = single 
agent prednisone<0.5 mg/kg/day; Moderate = prednisone ≥ 0.5 mg/kg/day and/or any single 
agent/modality; High = 2 or more agents/modalities ± prednisone ≥ 0.5 mg/kg/day. 148 
Disease was considered more active if the need for systemic immunosuppression was higher. 
b) Therapeutic intent at the time of visit/evaluation. The post-transplant course, history of 
cGVHD presentation, features, treatment, and therapeutic response were carefully 
documented in each subject participating in this study. Based on review of materials (prior 
medical records, including clinician progress notes, laboratory data, diagnostic tests/scans 
(e.g. PFTs, chest CT) and the in-depth comprehensive evaluation conducted over 4 days, after 
a detailed discussion we reached an interdisciplinary consensus on each case on the decision 
to increase, decrease or maintain the immunosuppressive regimen. 
Disease was defined as "active" if the practitioner decided to increase systemic therapy due to 
worsening disease, to substitute systemic therapy due to lack of response or withdraw 
systemic therapy due to lack of response. Disease was defined as "non-active" if the 
practitioner decided to decrease systemic therapy because the cGVHD was improving, not to 
change current systemic therapy because cGVHD was stable or to alter systemic therapy only 
because of toxicity. If patients either had not been receiving any immunosuppressive therapy 
at the time of evaluation or did not meet any of the previously mentioned criteria, they were 
categorized as "other" (excluded from the analysis) 
c) Clinician's global assessment of change over the past month (7-point scale): worsened (-3= 
very much worse, -2= moderately worse, -1= a little worse), unchanged (0= about the same), 
and improved (+1= a little better, +2= moderately better, +3= very much better). Based on our 
review of patient’s medical history and comprehensive clinical exam and evaluation, clinician 
had reached a decision on cGVHD trajectory. This particular question of whether cGVHD is 
better or worse over the preceding month is derived from NIH cGVHD response criteria 
evaluations (form A) Figure 9.A, which was originally based on the literature experience in 
other disease settings. This scale is based on the clinician’s subjective impression of cGVHD 
change over the past month and on patient’s symptoms and overall clinical history over the 
previous month. The limitation of this proposed instrument is the lack of a baseline 
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comparison and the consideration that assessment is heavily influenced by patient reported 
symptoms. 149 
 
4.2.3.2. cGVHD severity:  
cGVHD severity was defined by:  
a) Global NIH scoring (reflects the degree of organ impact and functional impairment due to 
cGVHD): 
Patients had mild cGVHD if only 1 or 2 organs (except lungs) were involved, with a 
maximum score 1 in all affected organs. Moderate cGVHD involved at least 1 organ with 
clinically significant, but not major disability (maximum score 2); or 3 or more organs with 
no clinically significant functional impairment (maximum score 1 in all affect organs). A lung 
score 1 was classified as moderate. Severe cGVHD indicated major impairment caused by 
cGVHD (score 3 in any organ). Lung scores of 2 or 3 were classified as severe. Organs scored 
included the skin, eyes, mouth, GI tract, liver, lungs, and joint/fascia. Of note, when scoring 
lung on the NIH score sheet, the lung function score (LFS) is used when pulmonary function 
tests (PFTs) are available and only in the absence of PFTs, are the symptoms used to grade 
lung. The LFS is computed by the extent of FEV1 and DLCO compromise (FEV1: >80%=1, 
70–79%=2, 60–69%=3, 50–59%=4, 40–49%=5, <40%=6; DLCO: >80%=1, 70–79%=2, 60–
69%=3, 50–59%=4, 40–49%=5, <40%=6; summary score (FEV1+DLCO): 2=LFS 1, 3–
5=LFS 2, 6–9=LFS 3, 10–12=LFS 4). When discrepancy existed between pulmonary 
symptom or PFT scores the higher value was used for final scoring. All but 3 patients had 
PFTs available for scoring in our study population (Figure 5). The genital area was scored in 
females only 16;  
b) NIH average score which is a result of total NIH score for each of the organ systems 
divided by the total number of organ systems analyzed (8 for female and 7 for male); 
 c) Lee symptom scale: degree of patient bother with cGVHD symptoms. It is a 30-item 
symptom scale with 7 subscales which correlate highly with patients' self-assessed mild, 
moderate, and severe cGVHD manifestations 150; 
d) Using the physical component summary (PCS) scale, drawn from the SF-36 v.2, a well 
validated measure of self-assessed health. The SF-36 Health Survey is a multi-purpose health 
survey which contains 36 questions. 36 items evaluate 8 factors: vitality, physical functioning, 
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bodily pain, general health perceptions, physical role functioning, emotional role functioning, 
social role functioning, and mental health. In addition to the individual subscale scores, 2 
component summary scores, physical (PCS) and mental (MCS) are computed through 
aggregation of the subscales. The SF-36 is a generic measure of health status as opposed to 
one that targets a specific age, disease, or treatment group. It has proven useful in comparing 
general and specific populations, estimating the relative burden of different diseases, 
differentiating the health benefits produced by a wide range of different treatments, and 
screening individual patients 151,152; 
e) Schirmer’s tear test performed in each eye with anesthesia scored from 0-30 mm;  
f) Oral Mucositis Rating Scale (OMRS) a rating scale (0-273) used to grade and measure oral 
changes including erythema, atrophy and ulceration 153;  
g) Percentage of skin body surface area (BSA) affected by: erythema, moveable sclerotic skin 
manifestations, and non-moveable skin changes and fasciitis. 149  
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4.2.4. Laboratory assessments 
4.2.4.1. Markers of inflammation 
• Chemistry: CRP, ferritin, complement total, C3, C4, albumin, ESR, IgG, IgM, IgA, 
beta-2 microglobulin, total protein 
• Hematology: WBC, ANC (absolute neutrophil count), lymphocytes (absolute 
lymphocyte count), eosinophils (absolute eosinophil count), platelet count 
 
4.2.4.2. Other laboratory assessment 
 CBC with differential, hemoglobin, bilirubin, AST, ALT, GTT, AP, GGT, creatinine, 
urea, potassium, sodium, calcium, magnesium, phosphorus, lipid panel and 
triglycerides, PT, PTT, quantitative serum immunoglobulins, autoantibodies panel, 
T3, T4, TSH, T4 free, testosterone (free and total), LH, FSH, estradiol, PTH, vitamin 
D 25, vitamin D 1,25, peripheral blood chimerism, hepatitis B and C serology, PCR 
CMV DNA, urine analysis, cyclosporine or tacrolimus level, peripheral blood 
immunophenotypization, amylase and lipase (if GI symptoms are present) 
Blood samples were submitted to the Department of Laboratory Medicine, Clinical Center, 
NIH for routine laboratory analysis. Serum albumin and total protein (TP) were analyzed with 
Synchron LX20 Chemistry Analyzer (Beckman Coulter Inc., Brea, CA) and Dimension Vista 
System (Siemens Healthcare Diagnostics Inc., Newark, DE).  Agreement between the two 
analyzers (slope/intercept) was verified using debiased (Deming) regression analysis 
(Albumin: 0.99/0.09; TP: 1.03/0.02). Serum CRP was measured by turbidimetry and C3, C4, 
IgG (immunoglobulin G), IgM (immunoglobulin M) and IgA (immunoglobulin A), and were 
measured by nephelometry using Beckman Coulter IMMAGE Immunochemistry System and 
Siemens Dimension Vista System.  The agreement between the two different methodologies 
was: CRP 0.96/0.39; C3 1.1/1.6; C4 0.96/0.5; IgA 0.95/8; IgM 1.02/ -3; IgG 
0.98/30.  Concentrations of serum beta-2-microglobulin, ferritin and parathyroid hormone 
were determined using a chemilumiluminescent immunometric assays on the Siemens 
Immulite 2500. ESR was analyzed on Excyte 40 Automated ESR Analyzer (Vital 
Diagnostics). CBC data was obtained using Automated Hematology Analyzers. 
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4.2.5. Statistical analyses  
Univariate analyses between a set of laboratory and clinical predictors and a set of cGVHD 
activity and severity definitions were initially performed to screen for associations between 
laboratory markers of inflammation and outcomes of interest.  Statistical methods used in 
these univariate analyses included the following: Wilcoxon rank sum test, Jonckheere-
Terpstra trend test, 154 Kruskal-Wallis test, and Spearman rank correlation. Spearman 
correlations are interpreted as follows: |r| >0.70=strong correlation; 0.5 < |r| <0.7=moderately 
strong correlation; 0.3 < |r| < 0.5= weak to moderately strong correlation; |r| <0.3=weak 
correlation. In view of the number of tests performed in univariate analyses, only p-values 
<0.01 are considered to be statistically significant while if 0.01 < p <0.05, the associations 
reflect strong trends. Laboratory parameters were compared with controls using a Wilcoxon 
rank sum test. Laboratory markers which were found to be potentially associated (p<0.05) 
with the outcomes of interest were then evaluated using univariate logistic regression 
analyses. Following univariate logistic regression analysis, multivariable logistic regression 
analysis was done to determine if any of the 24 laboratory parameters were associated with a 
set of outcomes after adjusting for a set of clinical and demographic parameters. Outcomes 
that were dichotomized were evaluated with respect to the significance of potential prognostic 
factors using univariate and then multiple logistic regression analysis. Outcomes that were 
classified into three ordered categories were evaluated for the effects of potential prognostic 
factors using logistic regression for ordered outcomes.  
Survival analyses were done beginning at the date of entry onto the natural history protocol 
until death or last follow-up, since the intervals from HSCT to cGVHD diagnosis or from 
cGVHD to on-study were not associated with survival and the laboratory data were known 
only at the time of enrollment. Kaplan-Meier analyses and log-rank tests were used to 
determine the association between potential predictors and survival after entering on the trial. 
P-values determined after an initial analysis identified groups to form with differing prognosis 
were adjusted by multiplying the p-value by the number of implicit tests performed to arrive 
at the final grouping. Following these univariate analyses, Cox proportional hazards models 
were constructed to determine the joint association between the factors of potential interest 
and survival. All p-values are two-tailed, and except as noted above, have not been adjusted 
for multiple comparisons.  
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5. Results 
5.1. Patient Characteristics  
Clinical, demographic and cGVHD-related characteristics of patients are summarized in 
Table 5. and Table 6. 
Median patient's age on study was 48 years [18-70 years] and 48% of patients were female 
and 52% were male. Median time from transplant to onset of cGVHD was 7 months [1.6-83]. 
Median time from transplant to enrollment was 37 months [4-258]. Median time from 
cGVHD diagnosis to enrollment was 23 months [0-222]. Median follow-up of surviving 
patients was 29.8 months [1-70]. The majority of patients (66%) had severe disease in terms 
of global NIH global score with a median of 4 organs involved [1-8]. Eighty patients (42%) 
had the progressive onset of the disease. (Figure 10.) One hundred forty (74%) patients 
received moderate or high intensity of immunosuppression and failed a median of 4 [range 0-
9] prior systemic therapies. Seventy-one (38%) of the patients were scored as active. Fifty-
seven patients (30%) were scored as worsened, 34 (19%) as improved and 64 (34%) as 
unchanged by clinician's global assessment of change over the previous month and for 34 
patients data were missing. Median NIH average score was 1.09 [0.14-2.14]. The median Lee 
symptom score was 34 [1-83]. Median PCS score using norm-based scoring (Physical) was 
34.75 [11.11-58.4]. Schirmer’s tear test median score was 3 [0-29.5]. Oral mucositis rating 
scale median score was 9 [0-60]. Six (3%) patients had more than 50 % of BSA (body surface 
area) affected by erythema, and 23 (12%) manifested 50% BSA sclerotic changes (moveable 
and/or non-moveable).  
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Table 5. Clinical, demographic and transplant characteristics (N=189) 
 
Characteristic  N (%)  N (%) Transplant 
related 
N (%) 
 Age   KPS  Donor  
< 40  58 (31)  ≤80 115 (61) Related 130 (69)  
40<x<60  110 (58)  80-100 70 (37) Unrelated 59 (31)  
>60  21 (11)  unknown 4 (2) Stem cell 
Source 
 
Gender   FEV1  Bone Marrow 35 
(18.5)  
Male  99 (52)  <57 47 ( 25) Peripheral 
Blood  
153 (81)  
Female  90 (48)  >57 139 (73) Cord Blood 1 (0.5)  
Disease   unknown 3 (2) HLA Matched  
ALL/AML/MDS  78 (41)  Creatinin
e 
 Yes 156 (83)  
CML  30 (16)  ≤1.2  142 (75) No 29 (15)  
CLL  14 (8)  >1.2 47 (25) Unknown 4 (2)  
Lymphoma  42 (22)  Bilirubin 
total 
 Myeloablative 
conditioning 
 
Multiple 
Myeloma  
15 (8)  ≤1 179 (95) Yes 102 (54)  
Aplastic 
Anemia/PNH  
  6 (3)  >1  10 (5) No 86 
(45.5)  
Other    4 (2)  LDH  Unknown 1 (0.5)  
CMV status at 
transplant 
 ≤226 123 (65) Acute GVHD  
Positive 59 (31) >226 66 (35) Yes 120 (63)  
Negative 
Unknown 
50 (27) 
80 (42) 
  No 69 (37)  
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Table 6. Chronic graft versus host characteristics (N=189) 
Characteristic N (%)  N (%) 
Time from 
transplant to 
enrollment  
 Intensity of 
immunosuppression* 
 
<1 year  30 (16)  None/Mild 49 (26) 
1-2 years  23 (12)  Moderate 71 (37) 
2-3 years  41 (22)  High 69 (37) 
3-5 years  44 (23)  Activity by 
Therapeutic Intent** 
 
>5 years  51 (27)  Active 71 (38) 
cGVHD 
Onset  
 Non Active 84 (44) 
Progressive  80 (42)  Unknown 34 (18) 
Quiescent  41 (22)  NIH global score***  
De Novo  67 (35.5)  Mild 2 (1) 
Unknown  1 (0.5)  Moderate 62 (33) 
Classification 
of cGVHD  
 Severe 125 (66) 
Classic  166 (88)  Number of organs 
involved  
 
Overlap  23 (12)  1-3  47 (25) 
Number of 
prior 
systemic 
treatments  
  4-6  
123 (65) 
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< 2  19 (10)  7-8  19 (10) 
2-3  72 (38)  Platelet count (K/µL)  
4-5  61 (32)  < 100,000  13 (7) 
>5  35 (19)  >100,000 176 (93) 
Unknown  2 (1)    
 
*** Mild chronic GVHD involves only 1 or 2 organs or sites with no clinically significant functional 
impairment (max score 1). Moderate involves at least 1 organ or site with clinically significant but no 
major disability (max score 2) or 3 or more organs or sites with no clinically significant functional 
impairment (max score 1). A lung score of 1 is also moderate chronic GVHD. Severe chronic GVHD 
indicates major disability caused by cGVHD (score 3). A lung score of 2 or 3 is also classified as 
severe cGVHD; * None/Mild=single agent prednisone<0.5 mg/kg/day; Moderate=single agent 
prednisone≥0.5mg/kg/day and/or any single agent/modality; High: 2 or more 
agents/modalities±prednisone≥0.5 mg/kg/day; ** Active: 1) increase systemic therapy because 
cGVHD is worse; 2) substitute systemic therapy due to lack of response; and 3) withdraw systemic 
therapy due to lack of response. Non-active: 1) decrease systemic therapy because cGVHD is better; 
2) not change current systemic therapy because cGVHD is stable; 3) alter systemic therapy due to its 
toxicity. Other: either did not receive any immunosuppressive therapy or did not meet any of criteria.  
NIH global score and organ involvement are shown in Table 7.  
Table 7. NIH cGVHD Scores 
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Figure 10. Types of cGVHD onset 
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Median age in the control group was 53 [37-67] and median time from transplant to 
enrollment was 23 months [4-127]. 
Three of seventeen controls were receiving "moderate intensity" of systemic 
immunosuppressive therapy (protocol planned tapering of GVHD prophylaxis) at the time of 
study enrollment. One was receiving cyclosporine A 100 mg daily, one cyclosporine A 125 
mg daily and one tacrolimus 1 mg daily.  
 
5.2. Comparison of laboratory parameters in patients with chronic GVHD and control 
group  
Laboratory parameters in patients with cGVHD and controls are shown in Table 8.  
Compared to non-cGVHD controls, patients with cGVHD had significantly higher CRP, 
WBC (white blood count), ANC (absolute neutrophil count) and platelet count and lower 
hemoglobin, albumin and TP values (Table 8.) In the univariate analyses only weak to 
moderately strong (0.3 < |r| < 0.5) correlations were found between laboratory parameters and 
continuous outcomes of BSA (body surface area) sclerotic changes (moveable and non-no 
moveable) and NIH average scores.  
Among categorical outcomes higher C4 levels were associated with lower Clinician global 
assessment of change, (e.g. cGVHD worsened; p=0.0011).  
Table 8. Laboratory parameters assessed and comparison to non GVHD controls  
 
Laboratory 
parameter 
Median (range) 
 
p-
value* 
 
Reference 
range 
cGVHD 
Patients 
(N=189) 
Non cGVHD 
HSCT Controls 
(N=17) 
CRP 
  
0.65 (0.02-15.4) 0.30 (0.07-1.50) 0.028 0-0.8 (mg/dL) 
WBC  
6.98 (1.96-31.3) 4.98 (2.48-9.29) 0.0012 4.23-9.07(K/ 
μL) 
ANC  4.14 (0.86- 2.30 (1.19-5.08) 0.0001 1.78-5.38(K/ 
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26.32) μL) 
Platelets  
247 (33-648) 197 (68-286) 0.013 161-347 (K/ 
μL) 
HGB  
12.7 (8.2-17.1)  13.8 (9.9-16.2) 0.022 13.7-17.7 
(g/dL) 
Albumin  
3.6 (1.9-4.8) 4.1 (3.2-4.7) <0.000
1 
3.7-4.7  (g/dL) 
TP  6.2 (3.9-8.9) 6.60 (5.1-8) 0.041 6.4-8.2 (g/dL) 
ALC  
1.27 (0.11-7.55) 1.69 (0.57-3.85) 0.13 1.32-3.57(K/ 
μL) 
AEC  
0.09( 0-3.47) 0.15 (0.02-0.37) 0.24 0.04-0.54(K/ 
μL) 
Ferritin  
387 (8-6426) 218 (34-1466) 0.27 18-370 
(mcg/L) 
β2-
microglobulin 
2.2 (0.9-22.9) 2.2 (1-8) 0.72 0.9-1.7 (mg/L) 
ESR  16 (2-123) 12 (2-72) 0.14 0-25 (mm/hr) 
IgG  
650 (98-3380) 793 (589-854) 0.63 642-1730 
(mg/dL) 
IgM  
51.5 (7-424)   34-342 
(mg/dL) 
IgA  
59 (10-647)   91-499 
(mg/dL) 
C3 comp  
132 (64-216)   90-180 
(mg/dL) 
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C4 comp  27 (13-74)   10-40 (mg/dL) 
Comp Total  
130 (9-228)   55-145(CAE 
U) 
PTH  44.3 (29-448)   16-87 (pg/mL) 
 
* as determined by Wilcoxon rank sum test; significant if p<0.05. 
 
5.2.1. APR values and activity and severity of cGVHD 
Patients with active disease had higher values of CRP (p=0.0001), C3 (p=0.0003), C4 
(p=0.0004) and platelets (p=0.012) as well as lower levels of albumin (p=0.044). Similarly, 
patients with severe NIH global score had higher values of CRP (p=0.0499), C3 (p=0.0017) 
and platelets (p=0.0028) compared to patients with moderate disease (Figure 11 A-E).   
 
 
  
   p=0.031 p=0.0001 p=0.0499
CRP 
mg/
dl 
A 
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C3 
mg/
dl 
p=0.0046 p=0.0017p=0.0003
C4 
mg/
dl 
B 
C 
p=0.0011 p=0.0004 n.s.
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n.s. p=0.012 p=0.0028
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Figure 11. Association between cGVHD activity/severity definitions and laboratory 
parameters 
Association between cGVHD activity/severity definitions and laboratory parameters 
presented as medians, 25th and 75th percentile and 1.5IQR (interquartile range) of the lower 
quartile (q1-1.5xIQR), and the 1.5IQR of the upper quartile (q3+1.5xIQR) for intensity of 
immunosuppression (gray), cGVHD activity (white) and cGVHD severity (black). 
Figure illustrates higher CRP (A) values in patients with higher immunosuppression and in 
those with active and severe disease. (B) Figure illustrates higher C4 values in patients with 
higher immunosuppression or with active and severe disease. (C) Figure illustrates higher C3 
values in patients with higher immunosuppression and with active disease. (D) Figure 
illustrates higher platelets values in active and severe disease. (E) Figure illustrates lower 
albumin levels in active disease; n.s. = not statistically significant.
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5.3. Univariate analyses of laboratory parameters and categorical outcomes intensity of 
immunosuppression, active vs. non-active disease and NIH global severity 
This data are shown in Table 9.  
Table 9. Univariate associations between laboratory parameters and categorical outcomes 
Paramet
er (units) 
median, 
[range] 
Intensity of 
immunosuppression 
 Activity by 
therapeutic 
intent 
 NIH global 
severity stage 
 
 none/m
ild 
(n=49) 
modera
te 
(n=71) 
high 
(n=6
9) 
p-
value* 
non-
activ
e 
(n=8
4) 
activ
e 
(n=7
1) 
p-
value*
mode
rate 
(n=6
2) 
severe 
(n=12
5) 
p-
value
* 
CRP 
(mg/dL)  
0.42 
[0.19-
4.43] 
0.63 
[0.02-
15.4] 
0.77 
[0.04
-
6.92] 
0.031 0.49 
[0.02
-
7.84] 
1.00  
[0.09
-
15.4] 
0.000
1 
0.49 
[0.02
-
7.84] 
0.76 
[0.03-
15.4] 
0.049
9 
C3 
(mg/dL ) 
129  
[66-
179] 
128  
[64-
210] 
147  
[76-
216] 
p=0.0
038# 
0.0046 126  
[64-
210] 
145  
[76-
216] 
0.000
3 
122  
[66-
187] 
139  
[64-
216] 
0.001
7 
C4 
(mg/dL) 
24  
[15-37] 
27  
[13-61] 
31  
[13-
74] 
p=0.0
01# 
0.0011 24  
[13-
74] 
31  
[15-
68] 
0.000
4 
25 
[13-
55] 
28 
[15-
74.1] 
0.09 
Comp 
total 
(CAE U) 
121   
[9-180] 
136 
[69-
228] 
136  
[21-
207] 
0.032 128 
[9-
198] 
135 
[21-
228] 
0.19 127 
[9-
197] 
136 
[48-
228] 
0.17 
IgG 
(mg/dL) 
887  
[200-
3380] 
p=0.00
03‡ 
570  
[98-
2190] 
580  
[142-
2050]
p=0.0
007# 
0.002 608 
[139-
3080]
599 
[98-
2190]
0.58 675 
[139-
3080] 
602 
[98-
3380] 
0.29 
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IgM 
(mg/dL) 
109 
[10-
413] 
p=0.00
11‡ 
41 
[7-424] 
42.5 
[10-
257] 
p<0.0
001# 
0.0003 41 
[10-
413] 
47 
[7-
424] 
0.76 42 
[10-
413] 
59 
[7-
424] 
0.63 
IgA 
(mg/dL) 
81 
[11-
647] 
p=0.00
14‡ 
54 
[10-
388] 
39.5 
[10-
258] 
p<0.0
001# 
<0.000
1 
55 
[10-
388] 
51 
[10-
647] 
0.61 60 
[10-
388] 
58 
[10-
647] 
0.49 
TP 
(g/dL) 
6.6 
[5.1-
8.9] 
6.1 
[4.2-
8.8] 
6.2 
[3.9-
7.7] 
p=0.0
044# 
0.013 6.2 
[4.7-
8.9] 
6.3 
[3.9-
8.8] 
0.24 6.2 
[3.9-
8.9] 
6.30 
[4.7-
8.8] 
0.2 
HGB 
(g/dL) 
13.3  
[10.7-
17.1] 
p<0.00
01‡ 
12.5  
[8.2-
16.1] 
12.3  
[8.9-
16.2] 
p=0.0
002# 
0.0006 12.5 
[8.2-
16.6] 
12.5 
[8.8-
16.2] 
0.8 12.9 
[8.2-
17.1] 
12.5 
[8.8-
16.2] 
0.28 
ALC 
(K/μL) 
1.63  
[0.34-
7.55] 
1.22  
[0.11-
5.00] 
1.00  
[0.15
-
5.30] 
p=0.0
046 #
0.011 1.19 
[0.11
-
6.88] 
1.21 
[0.15
-
5.30] 
0.58 1.33 
[0.11
-
6.88] 
1.19 
[0.15-
7.55] 
0.36 
β-2-
microglo
bulin 
(mg/L) 
2.10[1.
1-6.9] 
2.20[0.
9-22.9] 
2.60[
1.2-
5] 
0.046 2.1 
[0.9-
8] 
2.5 
[1-
6.7] 
0.16 2.5 
[1.1-
6.9] 
2.2 
[0.9-
22.9] 
0.25 
Platelets 
(K/μL) 
244  
[33-
471] 
224  
[49-
539] 
266 
 [34-
648] 
0.07 223  
[33-
465] 
278  
[56-
648] 
0.012 214  
[33-
461] 
265  
[34-
648] 
0.002
8 
Albumin 
(g/dL) 
3.7  
[2.5-
4.8] 
3.6 
[2.1-
4.4] 
3.6 
[1.9-
4.3] 
0.082 3.6 
[2.9-
4.6] 
3.5 
[1.9-
4.5] 
0.044 3.6 
[1.9-
4.8] 
3.6 
[2.1-
4.6] 
0.95 
Ferritin 
(mcg/L) 
200 
[32-
6426] 
464 
[23-
5401] 
421 
[8-
5961]
0.73 374 
[21-
6426]
448 
[8-
5961]
0.7 358 
[21-
6426] 
437 
[8-
5961] 
0.89 
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ESR 
(mm/hr) 
12 
[2-91] 
21 
[2-123] 
18  
[2-
80] 
0.15 15 
[2-
123] 
21 
[2-
95] 
0.063 21 
[2-
123] 
16 
[2-
116] 
0.63 
WBC 
(K/μL) 
6.31 
[2.27-
14.1] 
7.14 
[1.96-
27.85] 
7.14 
[2.47
-
31.3] 
0.65 6.62 
[2.27
-
19.40
] 
7.62 
[1.96
-
31.3] 
0.076 6.4 
[1.96
-
14.1] 
7.37 
[2.65-
31.3] 
0.1 
ANC 
(K/μL) 
3.58 
[1-
10.3] 
p=0.00
39‡ 
5.27 
[0.86-
26.32] 
3.99 
[1.05
-
18.3] 
0.32 4.13 
[1-
18.3] 
5.09 
[0.86
-
26.3] 
0.43 3.79 
[0.86
-
12.2] 
4.45 
[1.05-
26.3] 
0.08 
AEC 
(K/μL) 
0.12 
[0-
0.97] 
0.07 
[0-
1.26] 
0.09 
[0-
3.47] 
0.3 0.08 
[0-
1.26] 
0.1 
[0-
3.47] 
0.78 0.1 
[0-
3.47] 
0.08 
[0-
3.26 
0.14 
PTH 
(pg/mL) 
41.6 
[4.8-
161] 
44.6 
[5.7-
448] 
6.2 
[3.9-
7.7] 
0.76 45 
[2.9-
448] 
39 
[6.8-
256] 
0.72 41 
3.6-
273] 
45 
[2.9-
448] 
0.37 
 
* p-values for parameters across ordered intensity of immunosuppression were determined by 
Jonckheere-Terpstra test for trend, while those for therapeutic intent and NIH global severity 
were determined by Wilcoxon rank sum test. Across 'intensity of immunosuppression' 
categories parameters were compared between the two groups at a time using a Wilcoxon 
rank sum test.; If p<0.005 consider the difference to be significant while if 0.005 < p <0.05, 
this indicates a strong trend (bold). ‡None/mild significantly different from moderate, 
#None/mild significantly different from high. Moderate and high never differed significantly 
(p>0.005 in all cases). 
A statistically significant association was found between higher levels of CRP (p=0.0002), C3 
(p<0.0001) and platelets (p=0.0001) and more severe joint/fascia involvement (NIH score 3). 
Similarly, higher levels of CRP (p=0.0004), C3 (p<0.0001) and platelets (p=0.0016) were 
associated with more severe skin involvement (NIH score 3). 
No statistically significant association was found between ferritin, ESR, WBC, ANC, absolute 
eosinophil count and parathyroid hormone and clinical activity or severity outcomes.  
Serum cytokines (MCP1, IL-1RA, IL-6, and TNFRII) were measured in an exploratory 
analysis on a subset of 107 patients and there were no statistically significant association with 
cGVHD outcomes. 
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5.4. Multivariable model determining chronic GVHD activity and severity  
The following categorical outcomes were developed with a multivariable model:  
1. Intensity of immunosuppression, (none/mild vs. moderate vs. high) 
2. Active vs. non-active disease based on therapeutic intent  
3. NIH global score (moderate vs. severe) 
Continuous outcomes: Lee total score, SF36 physical, Schirmer’s tear test, OMRS, BSA 
erythema, non-moveable sclerosis/fasciitis and NIH average score were excluded from further 
analyses due to correlation coefficients with laboratory parameters of <0.40. Clinician’s 
global assessment and BSA moveable sclerotic changes were not found to be related to any 
laboratory markers in the final analysis, so no models were developed related to these 
outcomes.  
5.4.1. Intensity of immunosuppression (none/mild vs. moderate vs. high) 
The following variables were included in the initial multivariable model: CRP, C3, C4, 
complement total, IgG, IgM, IgA, total protein, hemoglobin, absolute lymphocyte count 
(ALC), beta-2-microglobulin, number of prior treatments and stem cell source.  
As expected, patients who were receiving high levels of immunosuppression had lower values 
of total protein, IgM, IgA, and received a greater number of prior treatments than patients 
who received moderate or low intensity immunosuppression, or who received low levels or 
no immunosuppression (Table 10.).  
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Table 10. Multivariable Cox proportional hazards model analysis of factors associated     
              with GVHD activity and severity 
 
Outcome  Parameter Estimate Standard error p-value  
Intensity of immunosuppression TP -0.2442 0.0681 0.0003 
 #Prior 
Treatments 
0.4303 0.082 <0.0001 
 IgA -0.0044 0.002 0.0278 
 IgM -0.0057 0.00197 0.0036 
Active vs. Non-active disease Albumin -1.013 0.1927 <0.0001 
 Platelets 0.00446 0.00205 0.0296 
 CRP 0.2567 0.1266 0.0427 
 #Prior 
Treatments 
0.4996 0.1163 <0.0001 
Global NIH severity Platelets 0.00395 0.00171  0.021 
 FEV1 -0.0251 0.0054 <0.0001 
 #Prior 
Treatments 
0.4991 0.1057 <0.0001 
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5.4.2. Clinician's therapeutic intention (active vs. non-active) 
The following variables were included in the initial multivariable model: CRP, C3, C4, 
platelets, albumin, number of prior treatments, FEV1 (forced expiratory volume in the first 
second), Karnofsky performance status and TBI (total body irradiation) conditioning. Logistic 
regression analysis showed that patients with active disease received more prior systemic 
therapies, and had higher values of CRP and platelets as well as lower values of albumin 
compared to patients with inactive disease (Table 10.).  Using this model the equation for 
predicting disease activity was established (Table 11.). Based on this rule, among those used 
to develop the rule, 71% of patients with active disease and 79 % of those with non-active 
disease would be correctly classified.  
 
Table 11. Equations predicting cGVHD activity and severity 
cGVHD                                                                     
active 398.05*albumin-1.74*platelets -194.40*number of prior treatments -
99.88*CRP <100  
non-active 398.05*albumin -1.74*platelets -194.40* number of prior treatments -
99.88*CRP >100 
severe -1.026*platelets -129.65 * number of prior treatments + 6.52*FEV1 <-100 
moderate -1.026*platelets - 129.65*number of prior treatments + 6.52*FEV1 >-100 
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An alternative model included the laboratory parameters of CRP, albumin, platelets, C3 and 
C4 complement. 
In this model, the thresholds for each parameter which provided the best classification to 
active/non-active disease were developed by individual logistic regression models. Each 
patient was then identified as to whether they were in the range associated with active disease 
by each of the 5 laboratory parameters. The total number of categories in which they would 
be classified as active was determined. The following describes the levels of the parameters 
which were associated with active disease: CRP>0.7 mg/dL, C3>140 mg/dL, C4>28 mg/dL, 
platelets>250 K/μL and albumin <3.6 g/dL. If 0-3 parameters fit these criteria, the chance of 
cGVHD to be active is 69%, and if all 5 parameters fit these criteria the chances of cGVHD to 
be active is 80%. If none of the parameters fits these criteria the chances of disease to be non-
active is 100% (Table 12.).  
 
12. Prediction of the cGVHD activity based on 5 laboratory parameters 
Parameter Active (80%)  Non-active (100%)  
CRP (mg/dL) ≥0.71 ≤0.71 
C3 (mg/dL ≥140 ≤140 
C4  (mg/dL) ≥28 ≤28 
Platelets  (K/μL) ≥250 ≤250 
Albumin  (g/dL) ≤3.6 ≥3.6 
 
 
1Thresholds shown were determined by univariate logistic regression model analyses. 
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Additional analysis to compare the group of the patients who did not receive any systemic 
immunosuppression (N=39) and the group of patients who received mild, moderate or high 
immunosuppression (N=150) has been also evaluated. There was a statistically significant 
difference (or a strong trend) between these two groups in the following laboratory 
parameters: patients receiving immunosuppression had higher values of CRP (p=0.048), 
complement total (p=0.0015), ferritin (p=0.022), ESR (p=0.018), and absolute neutrophil 
count (0.0011), likely reflecting active disease. The same group of patients had lower values 
of absolute lymphocyte count (p=0.0002), IgG (p<0.0001), IgM (p=0.0005), IgA (p<0.0001), 
total protein (p=0.0003), hemoglobin (p<0.0001), and AEC (p=0.016), that is probably the 
result of systemic treatment (Table 13.) 
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Table 13. Comparison of laboratory markers between patients who received and who did not 
receive systemic immunosuppressive treatment (only significant values shown)  
 
Parameter 
(units) 
median, 
[range] 
Intensity of immunosuppression p-value 
 None (n=39) Mild, Moderate or 
High (n=150) 
 
CRP 
(mg/dL)  
0.37 [0.19-
1.97] 
0.67 [0.015-15.4] 0.048 
Compl 
total 
(CAE U) 
117 [9-178] 136 [21-228] 0.0015 
IgG 
(mg/dL) 
906 [200-3380] 575 [98-2190] <0.0001 
IgM 
(mg/dL) 
109 [10-413] 43 [7-424] 0.0005 
IgA 
(mg/dL) 
87 [11-647] 50 [10-388] <0.0001 
TP 
(g/dL) 
6.7 [5.3-8.9] 6.2 [3.9-8.8] 0.0003 
HGB 
(g/dL) 
13.3 [10.7-
17.1] 
12.4 [8.2-16.6] <0.0001 
ALC 
(K/μL) 
1.817 [0.338-
7.548] 
1.120 [0.114-5.304] 0.0002 
Ferritin 
(mcg/L) 
170 [32-6426] 457 [8-5961] 0.022 
ESR 
(mm/hr) 
12 [2-91] 18 [2-123] 0.018 
ANC 
(K/μL) 
3.246 [1.001-
10.293] 
4.417 [0.862-
26.320] 
0.0011 
AEC 
(K/μL) 
0.122 [0.000-
0.973] 
0.08 [0.000-3.470] 0.016 
 
Parameters were compared between the two groups using a Wilcoxon rank sum test. 
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5.4.3. NIH global staging (moderate vs. severe) 
The following variables were included in the initial multivariable model: CRP, C3, platelets, 
number of prior treatments, age (continuous), FEV1, Karnofsky performance status and 
myeloablative conditioning. Patients with severe disease had higher platelet counts, received 
more prior systemic treatments, and had lower values of FEV 1 (Table 10.) Using this model 
the equation for predicting disease severity was established (Table 11.) Based on this rule, 
among those used to develop the rule, 76% of patients with severe disease and 74% of those 
with moderate disease would be correctly classified.  
Age, sex, donor type, cell source, conditioning regimen, Karnofsky performance status, time 
from transplant to enrollment, time from cGVHD diagnosis to enrollment, time from 
transplant to cGVHD diagnosis, gender match between recipient and donor, HLA (human 
leukocyte antigen) match, cGVHD classification (classic vs. overlap), cGVHD onset, 
eosinophil count (<0.5/>0.5 K/μL) and platelet count (<100/>100 K/μL) had no impact on 
disease activity or severity in any of the multivariate analyses. 
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5.5. Survival  
Overall survival on study is shown in Figure 12. 
Patients with active disease had decreased survival compared to patients with non active 
disease (p=0.057). Higher white blood count (adjusted p=0.029), higher absolute neutrophil 
count (adjusted p=0.05), lower lymphocyte count (adjusted p=0.057) and lower IgG (adjusted 
p=0.033) were shown to be associated with decreased survival in the univariate analysis 
(Figure 13. A-E).  
In the Cox proportional hazards model, in addition to higher Karnofsky performance status 
(>= 80; p=0.0008; Hazard ratio=0.33; 95 CI: 0.17-0.63), lower NIH lung score (0-2; 
p<0.0001; Hazard ratio=6.52; 95% CI: 3.07-13.87) and higher FEV1 (>57; p=0.0028; Hazard 
ratio=0.35; 95% CI: 0.18-0.70) higher absolute lymphocyte count (>0.65; p=0.017; Hazard 
ratio=0.43 (95% CI: 0.22-0.86) was the only laboratory marker associated with better survival 
from the day the patient went on study (Figure 14. A-C). The difference between active vs. 
non-active disease was not significant in the multivariable analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
 
 
Figure 12. Overall survival on study 
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A.  
 
 
 
 
 
 
 
 
 
WHITE BLOOD CELLS COUNT 
(p=0.029) 
≤ 9.7 
>9.7  
 77 
B. 
ABSOLUTE NEUTROPHIL COUNT 
(p=0.05) 
<3.05 
>3.05 
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C. 
ABSOLUTE LYMPHOCYTE COUNT 
(p=0.057) 
>0.65 
<0.65 
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D.  
IgG  
(p=0.033)
>650 
<650 
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E. 
 
Figure 13. Survival from study enrollment according to various laboratory parameters 
A. white blood cells count, B. absolute neutrophil count, C. absolute lymphocyte count,  
D. IgG, E. Active vs Non-active disease   
 
 
 
 
 
 
Active vs Non-active disease  
p=0.057 
Non-active 
Active 
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A.  
FEV1 
(>57; p=0.0028) 
>57 
<57 
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B.   
>=80 
<80 
KARNOFSKY 
(>= 80; p=0.0008) 
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C.
 
 
 
Figure 14. Association between demographic/clinical outcomes (A. FEV1, B. Karnofsky and 
C. NIH lung score) and survival 
NIH LUNG SCORE 
0-2 vs 3 
(p<0.0001) 
0-2 
3
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6. Discussion 
Chronic GVHD is the most severe late effect of therapy in survivors who undergo allogeneic 
HSCT. 155 It affects numerous organs, often requiring a comprehensive multidisciplinary 
approach and prolonged immunosuppressive therapy for a median duration of 2.5-3 years. 156 
The pathophysiology of cGVHD remains poorly understood, and the current mainstays of 
treatment are global immunosuppression rather than selective targeting of the key 
mechanisms of the disease. 157 First-line treatment with steroids with or without calcineurin 
inhibitor is successful in only about one-half of cases and there is no standard second-line 
treatment. 111,158  The decision whether to initiate, intensify, or taper immunosuppressive 
therapy is typically based on the clinician’s assessment of disease activity and severity. While 
suppression of disease activity is desirable to control symptoms and prevent irreversible 
damage, excessive immunosuppression of inactive cGVHD could be only harmful without 
resulting improvement in cGVHD manifestations. 159 In spite of advances in cGVHD staging 
based on NIH consensus criteria, there are no defined clinical measures to differentiate 
cGVHD disease activity (by definition, reversible manifestations of the disease) 149 vs. 
damage to guide clinical therapy decisions or monitor outcomes. We performed this study in a 
referral cohort of cGVHD patients highly enriched for those with established, severe and 
heavily previously treated disease. All patients were evaluated in depth and at the single time-
point in their disease trajectory and the sera samples were well annotated using a 
multidimensional battery of cGVHD descriptors.  
This study identified a number of laboratory indicators of inflammation (CRP, WBC, ANC, 
platelets and albumin) differing between patients with primarily established, moderate or 
severe cGVHD and non-cGVHD transplanted controls, suggesting ongoing tissue 
inflammation in the patient cohort. We also identified several laboratory markers associated 
with the clinicians’ assessment of disease activity or severity.  
CRP is the best known acute phase serum protein which is widely used as a marker of 
intensity of inflammatory process and shows strong interactions with the complement 
system.139 Values greater than 1 mg/dL (10 mg/L) reflect clinically significant inflammation. 
123,125 Values between 0.3-1mg/dL (3-10 mg/L) indicate "low grade inflammation" described 
in various chronic diseases. 160 The role of CRP and other routinely used clinical laboratory 
indicators of inflammation are unknown in the setting of cGVHD in contrast to their well 
established role in other inflammatory conditions and autoimmune disease such as rheumatoid 
arthritis, SLE or Crohn’s disease. 126,161  
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The role of CRP in cGVHD is suggested by few reports. 162,163 In the study performed  by 
Rovo et al. recipients had a decreased kidney function and higher liver function tests, except 
for bilirubin and higher TSH independent of presence or absence of cGVHD no difference 
existed between laboratory markers of inflammation between recipients without cGVHD and 
healthy donors. Patients with ongoing cGVHD had higher CRP (p=0.002) and vWF (p=0.002) 
values than patients without cGVHD and healthy donors. In addition patients with cGVHD 
had significantly lower albumin values (p=0.021). 163 
Our study demonstrated higher levels of CRP in sera of patients with active and severe 
disease compared to patients with non-active or moderate disease. The median CRP was 0.65 
mg/dL (6.5 mg/L), which is in the range of minor CRP elevation (0.3-1 mg/dL), described as 
"low grade inflammation" in chronic inflammatory conditions that differs from acute 
inflammation caused by infection not only in magnitude but also by absence of the classic 
clinical signs of infection. 160 In this study all patients underwent detailed clinical evaluations, 
and only a small minority had active infections (3%) and most of them had concurrent active 
cGVHD, emphasizing the need for interpreting laboratory markers in such cases with caution 
and strictly in the context of all other clinical information. 
Because active infections may influence CRP levels, we gave special attention to this during 
the data analysis. Microbiologic evaluation was not part of the routine clinical testing. 
However, during the detailed clinical evaluations we did look thoroughly for signs of 
infection and in case of any suspicion for an active infection further clinical and laboratory 
testing were pursued including an infectious disease consult. Six of seventy-seven patients 
with elevated CRP (>0.8 mg/dL) had documented infection (positive blood cultures and acute 
sinusitis). Three patients had positive blood cultures. The first patient reported occasional 
chills and his temperature was 37°C. He had Streptococcus bovis isolated from his blood 
culture and also Comamonas testosterone and Agrobacterium radiobacter isolated from his 
wound culture. His CRP was 2 mg/dL. The second patient reported temperatures up to 38°C 
two days before enrollment. His temperature at enrollment was normal. He had 
Staphylococcus epidermidis isolated from his blood cultures. He has also had Staphylococcus 
aureus isolated from his lung biopsy specimen. His CRP was 3.14 mg/dL. The third patient 
had CMV PCR positive blood (41 900 copies) with normal body temperature and no other 
signs of infection. CMV PCR testing is a standard part of this protocol. His CRP was 2.7 
mg/dL. One patient had thumb paronychia with isolated Staphylococcus aureus and no other 
signs of infection. His CRP was 5.15 mg/dL. Two patients had acute sinusitis and their CRP 
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values were 8.01 and 15.4 mg/dL. One patient with normal CRP (0.55 mg/dL) had E.coli and 
Staphylococcus coagulase negative isolated from her blood cultures.  Median CRP in this 
group was 4.15 mg/dL [2-15.4]. Because of the small number of patients (3% of the whole 
cohort) and because of the co-existence of active cGVHD in five patients they were kept in 
the study.  
In a study performed by Uguccioni et al. no significant increase in SAA or CRP was found in 
chronic GVHD in contrast to patients with aGVHD and graft rejection who were transplanted 
for β-thalassemia. The different acute phase response in acute GVHD and rejection compared 
with chronic GVHD suggests different immunopathogenic mechanisms are responsible. 164  
Complement activation is increasingly recognized as a major contributor to vascular 
inflammation.  
C3 deposits can be found in the skin, 165 and in glomerular membranes in patients with 
cGVHD and nephrotic syndrome with normal C3 and C4 serum levels. 166,167 Elevated 
complement and complement activation by autoantibodies is one of the possible mechanism 
of endothelial damage and fibrosis in SSc patients. 168 In our study higher levels of C3 and C4 
were associated with active disease, most likely as response to increased inflammatory 
cytokines such as IL-6. 116 Higher C3 levels were associated with most severe (sclerotic) 
changes skin (p<0.0001) and joint/fascia involvement (p<0.0001).  
It was mentioned earlier that thrombocytopenia in cGVHD patients is among the most 
consistent and strongest poor survival predictors in many cGVHD studies. 83 One of the 
earliest studies which showed that cGVHD patients with low platelet counts had the worst 
survival and that thrombocytopenia may reflect more severe cGVHD was study by First and 
colleagues published in 1985. 94 They found that among 65 patients who had full engraftment 
after alloHSCT, and who survived at least 60 days after transplantation, 24 (37%) developed 
isolated thrombocytopenia, 9 (14%) with transient and 15 (23%) with chronic 
thrombocytopenia (defined as platelet count remaining below 100,000/µL through day +120). 
The transient syndrome was not associated with adverse outcome, but patients with chronic 
thrombocytopenia had increased mortality and an increased risk of having severe acute and 
chronic graft versus host disease. Although bleeding complications in that study contributed 
directly to death in just two patients with chronic thrombocytopenia, there was a significantly 
higher mortality among cGVHD patients with chronic thrombocytopenia than in cGVHD 
patients with only transient or no thrombocytopenia. The authors concluded that observed low 
platelet count may be a marker for a more severe form of cGVHD. 94 A few years later 
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Sullivan et al studied 179 patients with extensive cGVHD, and found that those with platelets 
below 100,000/µL had increased mortality. 92 Another important work was published in 1989 
by Anasetti et al. 86 They assessed mechanisms of persistent thrombocytopenia in 20 patients 
who were between 60 and 649 days (median 90) after alloHSCT; among them 17 had isolated 
thrombocytopenia, 10 aGVHD and 6 cGVHD. 86 Platelet survival studies demonstrated that 
platelets persisted in the circulation for a shorter period of time in patients with GVHD, and in 
all studied patients a direct relationship between platelet survival and platelet count was 
observed. Moreover, platelet autoantibodies were found in five of six patients with acute or 
chronic GVHD, and in none of six patients without GVHD. 86 The investigators concluded 
that persistent thrombocytopenia after HSCT is most often due to increased platelet 
destruction mediated by multiple mechanisms, that immune deregulation accompanying 
GVHD may produce autoimmune thrombocytopenia, and that increased mortality of cGVHD 
patients with thrombocytopenia may be result of underlying immunodeficiency and immune 
deregulation. 86 Akpek et al defined 3 risk factors at diagnosis of cGVHD that were 
significantly associated with increased non-relapse mortality: platelets less than 100,000/µL, 
more than 50% body surface area skin involvement and progressive type of cGVHD onset.  87 
Study of Przepiorka et al validated risk stratification by platelet count in 116 alloHSCT 
patients. 90 Long term progression-free survival was 31% for patients without cGVHD, 51% 
for not thrombocytopenic cGVHD patients and just 16% for patients with cGVHD and 
platelets less than 100,000/µL.  90 Another large multicenter study published in 2003 with a 
total of 1105 cGVHD patients from 4 different cohorts showed that thrombocytopenia was 
uniformly associated with increased risk of mortality across all cohorts. 96 Arora et al studied 
159 cGVHD patients to identify predictors of response and long-term mortality. 169 In 
multivariate analysis age older than 20 years, progressive onset of cGVHD, gastrointestinal 
tract involvement and platelets less than 100,000/µL were associated with increased mortality. 
169 Pavletic et al described several independent prognostic risk factors for cGVHD incidence 
and severity comparing bone marrow (75 patients) and peripheral blood alloHSCT (87 
patients) recipients, suggesting that stem cell source may influence not just the incidence of 
cGVHD but also its characteristics. 84 Negative predictive factors for survival at 3 years after 
cGVHD diagnosis in allo-PBSCT patients were platelets less than 100,000/µL and history of 
aGVHD of the liver, and only thrombocytopenia remained predictive for poor survival in allo-
BMT group. 84 Another work of Arora et al published in 2007 analyzed clinical presentation 
and response to treatment in 170 patients with cGVHD; 123 after transplant from an unrelated 
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donor and 47 from umbilical cord blood. 89 In both cohorts thrombocytopenia and not 
achieving remission at 2 months were independently associated with increased mortality. 89  
In spite of such well known association of thrombocytopenia with negative survival of 
cGVHD patients, in this study low platelets were not prognostic for survival, possibly due to 
only 7% of patients with platelets <100 K/μL or because of long time from cGVHD diagnosis 
to enrollment (median 23 months). Surprisingly, higher platelet counts were associated with 
more active and severe cGVHD in this cohort. 
Platelets play important roles in hemostasis, thrombosis, inflammation, and vascular injury, 
and interaction of inflammation and hemostasis is described in many different settings. 
Inflammation is one of the causes of reactive thrombocytosis, mediated by IL-6, a strong 
stimulator of platelet production. 170 Also, data suggests that platelets express an intrinsic 
capacity to interact with and trigger both classical and alternative pathways of complement. 
Under pathologic conditions, complement activation on/by platelets may contribute to 
thrombosis and thrombocytopenia. 171 In addition to that, platelets can contribute to 
pathogenesis of fibrosis as they are important source of growth factors such as TGF-β and 
PDGF, which stimulate fibrosis and vascular thickening. 172,173 Indeed, in this study higher 
platelets were associated with most severe skin (p=0.0016) and joint/fascia involvement 
(p=0.0001). Moreover, it was recently found that active thrombopoiesis, measured by the 
absolute immature platelet number in the blood, was associated with worse severity and 
activity of chronic GVHD, especially skin and joints/fascia manifestations, supporting 
hypothesis that ongoing inflammation in cGVHD stimulates increased thrombopoiesis. 174 
Eosinophilia was infrequently observed in this patient population (n=14), and did not came up 
significant in any analysis done in this study. Eosinophilia has been identified as a forerunner 
to the development of both aGVHD and cGVHD 175, 176 and some studies have further shown 
an association with eosinophilia and favorable outcomes following allo-HSCT 177 and lower 
grade cGVHD 178. One retrospective study reported eosinophilia as a favorable prognostic 
factor for survival in patients with cGVHD 179 and another did not find any correlation 180,181 
None of these studies used NIH criteria and eosinophilia was identified at the time of cGVHD 
diagnosis, which differs from this current patient population. Eosinophilia in our patient 
population did not correlate with any specific clinical manifestations or laboratory parameter. 
Although cytokines (MCP1, IL-1RA, IL-6, and TNFRII) measured in this study on a subset of 
107 patients did not have statistically significant association with GVHD outcomes their role 
in cGVHD is very important as reported in many studies as potential targeted therapy. For 
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instance, very recent study published by Zeiser et al showed impressive results in cGVHD 
treatment with JAK1/2 inhibitor ruxolitinib. 182 JAK1/2 signaling has been shown to be 
crucial in various steps leading to inflammation and tissue damage in GVHD. A critical event 
involved in T cell activation, lineage commitment and survival is signaling through the 
common gamma chain, a constituent of the receptor complexes for six different interleukins: 
IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. 183 Common gamma chain signaling occurs via 
JAK1 and we were recently able to identify the common gamma chain as a potent therapeutic 
target in aGVHD and cGVHD. 184 In this study ruxolitinib was given as salvage-treatment in 
patients suffering from steroid refractory cGVHD. Investigators observed high response rates 
(>80%) and 6-month survival rates, although the patients were heavily pretreated and all had 
moderate or severe form of cGVHD. 182 
Olivieri et al. have reported several reports of treating steroid-refractory cGVHD with 
imatinib that has anti-PDGFR activity. After 6 months, intention-to-treat analysis of 39 
patients who received imatinib, regardless of the duration of treatment, revealed 14 partial 
responses (PR), 4 minor responses (MR) with relevant steroid sparing (46%) according to 
Couriel criteria, and 20 ≥ PR (51.3%), as per the National Institutes of Health (NIH) criteria 
and NIH severity score changes. Monitoring of PDGF-R antibodies showed a significant 
decrease in PDGF-R stimulatory activity in 7 responders, whereas it remained high in 4 
nonresponders. 185 
Imatinib mesylate represents a novel targeted approachto the management of sclerotic GVHD 
through inhibition of specific signaling pathways implicated in skin fibrosis. Imatinib has 
inhibitory activity against PDGFR. Elevated PDGF and its receptor have been found in the 
skin and bronchoalveolar lavage fluid in patients with systemic sclerosis. 186,187 
Stimulatory PDGF receptor antibodies have been described in patients with systemic sclerosis 
and extensive cGVHD, suggesting a direct mechanistic link to skin fibrosis via the PDGF 
pathway 63 Recent pilot phase II prospective study by Baird et al showed interesting results 
treating steroid refractory, sclerotic cGVHD with joint involvement. Fourteen (of 20 total) 
patients were assessable for primary response, improvement in joint ROM deficit, at 6 
months. Primary outcome criteria for partial response was met in 5 of 14 (36%), stable 
disease in 7 of 14 (50%), and progressive disease in 2 of 14 (14%) patients. 188 
Finally, we have clinically defined and validated by correlations with markers of tissue 
inflammation the definitions of cGVHD activity and severity, which could prove useful and 
feasible for clinical management and outcomes in trials. Of interest, distinct parameters were 
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associated with survival vs. disease activity. Higher WBC and ANC were associated with 
decreased survival, which could be a reflection of cytokines related to inflammation or a need 
for more systemic steroid therapy in patients with more severe cGVHD. By comparison, 
lower lymphocyte counts and IgG levels were also associated with decreased survival, and 
likely reflect higher burden of immunosuppression and more advanced cGVHD.  
Prospective studies using the 2005 cGVHD Consensus criteria have shown that skin score, 
lung score and GI score each predict the risk of TRM. 189,190,191,192 Previous studies have 
identified several factors associated with worse survival such as decreased performance 
status, thromcocytopenia at the time of diagnosis (<100,000/mcgL), multiple organ 
involvement, progressive onset, hyperbilirubinemia and a higher percentage of skin 
involvement at the time of diagnosis. 78,193,194,31,88,92,195 
In this study factors associated with worse survival were higher white blood count (p=0.029), 
higher absolute neutrophil count (p=0.05), lower lymphocyte count (p=0.057) and lower IgG 
(p=0.033), in the univariate analysis (Figure 13.). In the Cox proportional hazards model 
higher absolute lymphocyte count (>0.65; p=0.017; HR=0.43 (95% CI: 0.22-0.86), higher 
Karnofsky performance status (>=80; p=0.0008; HR=0.33; 95 CI: 0.17-0.63) and higher 
FEV1 (>57; p=0.0028; HR=0.35; 95% CI: 0.18-0.70) were associated associated with better 
survival (Figure 14.). 
Iron overload is an adverse prognostic factor in patients undergoing allogeneic stem cell 
transplantation for thalassaemia 196. Serum ferritin is an indicator for iron stores and elevated 
levels are associated with worse outcomes following transplantation. 197 Iron overload, 
primarily due to multiple red blood cell transfusions, is a relatively common complication in 
allo-HSCT recipients. Elevated pretransplant ferritin levels have been reported to increase the 
risk of non-relapse mortality following HSCT and lower incidence of acute and cGVHD. 145 
Iron availability influences innate and acquired immune responses. Reduced CD8+ T-cell 
counts have been observed in patients with iron overload. 142 In our study cGVHD patients 
had higher ferritin levels, compared to control group but not statistically significant, and did 
not correlate with intensity of immunosuppression, disease activity or NIH global severity 
score. 
In an additional analysis, patients receiving systemic immunosuppression, compared to ones 
who did not, had higher values of CRP, ferritin, and ANC, likely reflecting active disease and 
lower values of ALC and IgG, that is probably the result of treatment (Table 13.). 
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We developed a prognostic model and equations prediction for active and severe disease. 
Using this model the equation for predicting disease activity was established. Based on this 
rule, 71% of patients with active disease and 79 % of those with non-active disease would be 
correctly classified. Also, equation for predicting disease severity was made and based on 
developed equation, 76% of patients with severe disease and 74% of those with moderate 
disease would be correctly classified (Table 11.). 
This present study has several potential limitations. First, its cross-sectional design does not 
allow longitudinal monitoring of identified markers to see if there is an improvement in 
responding patients. Second, due to the nature of referrals to the NIH, the study population is 
enriched for severe cases of cGVHD; therefore, further investigation is needed to determine if 
the factors identified are applicable to patients with newly diagnosed and untreated disease. 
Because of the nature of a cross-sectional study and because this represents a referral 
population, our population was enriched for refractory or persistent cGVHD manifestations. 
We identified a high incidence of lung, sclerotic skin and joint/fascia involvement. In the 
same manner, the time from transplant in our population (approximately one-half of patients 
were >3 years from transplant) is not representative of all time points in the cGVHD disease 
course, particularly the onset of cGVHD manifestations. 
Lastly, cytokines of interest were studied only in sera and in a smaller number of patients 
limiting the ability for more detailed investigation of biological mechanisms of inflammation 
in cGVHD. The strengths of the study include the large prospectively acquired cohort of 
patients enriched for severe cGVHD and the systematic thorough characterization of cGVHD 
manifestations with laboratory correlates. 
In summary, we identified a number of clinical laboratory marker candidates, which could 
serve as surrogate measures for disease activity. The findings of associations between 
laboratory markers of inflammation and clinical outcomes support using the cGVHD activity 
defined by clinician’s intention and the NIH global severity as endpoints in clinical trials and 
practice. We also determined that laboratory factors predictive of survival differ from those 
predicting cGVHD activity, suggesting that active inflammation may not necessarily 
adversely impact long term prognosis if the cumulative damage from the disease and its 
treatments could be prevented. 156 Also, these results imply that disease activity may not be 
used as an adequate short term surrogate endpoint for survival outcomes.  
Future longitudinal studies in more diverse cGVHD patient populations, particularly in 
conjunction with treatment trials will be integral to understand the mechanisms of these 
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observed laboratory changes and how they are implicated in cGVHD. Most importantly, the 
findings presented here may be ultimately relevant for characterizing and monitoring cGVHD 
disease activity and predicting of survival that may aid in the evaluation of future treatment 
strategies.111, 198 
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7. Conclusions 
1. Patients with cGVHD had significantly higher CRP, WBC, ANC, platelet count and lower 
hemoglobin, albumin and total proteins values, compared to non-cGVHD controls. 
2. Patients with active disease had higher values of CRP (p=0.0001), C3 (p=0.0003), C4 
(p=0.0004) and platelets (p=0.012) as well as lower levels of albumin (p=0.044).  
3. These clinical laboratory markers of inflammation could serve as surrogate measures for 
disease activity. 
4. Patients with severe NIH global score had higher values of CRP (p=0.0499), C3 
(p=0.0017) and platelets (p=0.0028) compared to patients with moderate disease. 
5. Multivariable analyses showed:  
a) patients with active disease received more prior systemic therapies, had higher 
values of CRP and platelets as well as lower values of albumin compared to 
patients with inactive disease. 
b) Patients with severe disease had higher platelet counts, received more prior 
systemic treatments, and had lower values of FEV 1. 
c) patients receiving immunosuppression had higher values of CRP, complement 
total, ferritin, and absolute neutrophil count, likely reflecting active disease. 
Also, they had lower values of absolute lymphocyte count, IgG, IgM, IgA, 
total protein, hemoglobin, and AEC, that is probably due to systemic 
treatment.  
6. The chances of cGVHD to be active is 80% if CRP>0.7 mg/dL, C3>140 mg/dL, C4>28 
mg/dL, platelets>250 K/μL and albumin <3.6 g/dL.  
7. In the univariate analysis higher white blood count (p=0.029), higher absolute neutrophil 
count (adjusted p=0.05), lower lymphocyte count (p=0.057) and lower IgG (p=0.033) were 
shown to be associated with decreased survival. 
8. In the Cox proportional hazards model higher absolute lymphocyte count (>0.65; p=0.017; 
HR=0.43 (95% CI: 0.22-0.86), higher Karnofsky performance status (>= 80; p=0.0008; 
HR=0.33; 95 CI: 0.17-0.63), lower NIH lung score (0-2; p<0.0001; Hazard ratio=6.52; 95% 
CI: 3.07-13.87) and higher FEV1 (>57; p=0.0028; HR=0.35; 95% CI: 0.18-0.70) were 
associated associated with better survival from the day the patient went on study. 
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9. Clinical laboratory markers of inflammation predictive of survival differ from those 
predicting cGVHD activity, suggesting that active inflammation may not necessarily 
adversely impact long term prognosis if the cumulative damage from the disease and its 
treatments could be prevented. 
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8. Summary 
Chronic graft versus host disease (cGVHD) remains the major cause of non-relapse morbidity 
and mortality after allogeneic hematopoietic stem cell transplantation. Currently there are no 
accepted measures of cGVHD activity to aid in clinical management and disease staging. We 
performed this study in a cohort of cGVHD patients highly enriched for those with 
established, severe and previously heavily treated disease. All patients were evaluated, and at 
a single time-point in their disease trajectory, the sera samples were well-annotated using a 
multidimensional battery of cGVHD descriptors. We analyzed clinical markers of 
inflammation in the sera of patients with established cGVHD and correlated those with 
definitions of disease activity. 189 adult patients with cGVHD (33% moderate and 66% 
severe according to NIH global scoring) were consecutively enrolled into a cross-sectional 
prospective cGVHD natural history study. At the time of evaluation, 80% were receiving 
systemic immunosuppression and failed a median of 4 prior systemic therapies for their 
cGVHD. This study identified a number of laboratory indicators of inflammation differing 
between patients with primarily established, moderate, or severe cGVHD and non-cGVHD 
transplanted controls, suggesting ongoing tissue inflammation in the patient cohort. We also 
identified several laboratory markers associated with the clinician's assessment of disease 
activity or severity. Lower albumin (p<0.0001), higher CRP (C-reactive protein; p=0.043), 
higher platelets (p=0.030) and higher number of PST (p<0.0001) were associated with active 
disease defined as clinician's intention to intensify or alter systemic therapy due to the lack of 
response. Higher platelet count (p=0.021) and higher number of PST (p<0.0001) were 
associated with more severe disease as defined by NIH global score. In the Cox proportional 
hazards model, better Karnofsky performance status (>= 80; p=0.0008; Hazard ratio=0.33; 95 
CI: 0.17-0.63), higher FEV1 (>57; p=0.0028; Hazard ratio=0.35; 95% CI: 0.18-0.70) and 
higher absolute lymphocyte count (>0.65; p=0.017; Hazard ratio=0.43 (95% CI: 0.22-0.86) 
were associated with better survival. We developed a prognostic model and prediction 
equations for active and severe disease. Using this model (Table 10.), the equation for 
predicting disease activity was established. Based on this model, 71% of patients with active 
disease and 79 % of those with non-active disease would be correctly classified. Also, the 
equation for predicting disease severity was made and based on the developed equation, 76% 
of patients with severe disease and 74% of those with moderate disease would be correctly 
classified. This study identified common laboratory indicators of inflammation that can serve 
as markers of cGVHD activity and severity.  
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9.  Sažetak 
Kronična reakcija davatelja protiv primatelja (cGVHD) ostaje glavni uzrok morbiditeta koji 
nije povezan s relapsom i mortaliteta nakon transplantacije alogeničnih krvotvornih matičnih 
stanica. Trenutno ne postoje prihvaćene mjere cGVHD aktivnosti koje pomažu u kliničkom 
upravljanju i stupnjevanju bolesti. Istraživanje je provedeno na kohorti bolesnika s cGVHD-
om koja je uključivala velik broj onih s utvrđenom bolesti, ozbiljnim stupnjem bolesti te onih 
kod kojih je bolest prethodno višestruko liječena. Svi su bolesnici evaluirani te su u jednoj 
točki tijeka bolesti uzorci seruma temeljito opisani nizom multidimenzionalnih deskriptora 
cGVHD-a. Analizirani su klinički markeri upale u serumima bolesnika s utvrđenim cGVHD-
om i korelirali ih s definicijama aktivnosti bolesti. 189 odraslih bolesnika sa cGVHD-om 
(33% umjereni i 66% teški oblik prema NIH globalnom skoringu) je konsekutivno upisano u 
cross-sectional prospektivno istraživanje prirodnog tijeka cGVHD-a. U vrijeme evaluacije, 
80% je primalo sistemsku imunosupresiju te je medijan neuspješnih prethodnih sistemskih 
terapija za cGVHD bio 4. Ova je studija identificirala niz laboratorijskih pokazatelja upale 
koji se razlikuju među bolesnicima s primarno utvrđenim, umjerenim i teškim oblikom  
cGVHD-a i bolesnicima koji su transplantirani no nemaju cGVHD, što sugerira aktivnu upalu 
tkiva u kohorti bolesnika. Također smo identificirali nekoliko laboratorijskih markera 
povezanih s  procjenom aktivnosti ili težine bolesti koju donosi kliničar. Niži albumin 
(p<0.0001), viši CRP (C-reaktivni protein; p=0.043), viši trombociti (p=0.030) i više 
vrijednosti PST-a (p<0.0001) povezani su s aktivnom bolešću koja se definira kao namjera 
kliničara da intenzivira ili mijenja sistemsku terapiju zbog nedostatka odgovora. Veći broj 
trombocita (p=0.021) i veća razina PST-a (p<0.0001) povezani su s težim oblikom bolesti 
prema NIH globalnom skoringu. U Coxovom regresijskom modelu, bolji Karnofskyjevom 
skalom izvedbenog statusa (Karnofsky Performance Status) (>= 80; p=0.0008; Omjer 
hazarda=0.33; 95 CI: 0.17-0.63), veći FEV1 (>57; p=0.0028; Omjer hazarda =0.35; 95% CI: 
0.18-0.70) i viša apsolutna vrijednost limfocita (>0.65; p=0.017; Omjer hazarda=0.43 (95% 
CI: 0.22-0.86) su povezani s boljim preživljenjem. Razvijen je prognostički model i 
jednadžbe za predikciju za aktivne i teške oblike bolesti. Koristeći se ovim modelom (Tablica 
10), utvrđena je jednadžba za predviđanje aktivnosti bolesti. Na temelju tog modela, pravilno 
je klasificirano da 71% bolesnika ima aktivnu bolest, a 79% neaktivnu bolest. Također je 
izrađena i jednadžba za predviđanje težine bolesti, na temelju koje je pravilno klasificirano da 
76% bolesnika ima težak oblik bolesti, a 74% umjereni oblik bolesti. Ovim su istraživanjem 
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identificirani laboratorijski pokazatelji upale koji mogu služiti kao markeri za aktivnost i 
težinu cGVHD-a. 
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